The    O
most    O
common    O
applications    O
are    O
used    O
as    O
fluorescent    O
probes    O
,    O
either    O
directly    O
or    O
indirectly    O
,    O
such    O
as    O
aminoallyl    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
,    O
which    O
are    O
used    O
to    O
label    O
cRNA    O
or    O
cDNA    O
in    O
microarrays    O
.    O

Vidarabine    B-Nucleotide114964590
or    O
9-β-D-arabinofuranosyladenine    B-Nucleotide114964590
(ara-A)    I-Nucleotide114964590
is    O
an    O
antiviral    O
drug    O
which    O
is    O
active    O
against    O
herpes    O
simplex    O
and    O
varicella    O
zoster    O
viruses    O
.    O

Vidarabine    B-Nucleotide114964590

File    O
:    O
Vidarabine    B-Nucleotide114964590

It    O
is    O
often    O
added    O
to    O
foods    O
in    O
conjunction    O
with    O
disodium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
;    O
the    O
combination    O
is    O
known    O
as    O
disodium    B-Nucleotide114964590
5'-ribonucleotides    I-Nucleotide114964590
.    O

Disodium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
vomilenine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Nucleotide114964590
and    O
raucaffricine    O
.    O

Matching    O
these    O
structural    O
relationships    O
,    O
GPR17    O
has    O
been    O
reported    O
to    O
be    O
activated    O
by    O
cysteinyl    O
leukotrienes    O
(    O
i.e.    O
LTC4    O
and    O
LTD4    O
)    O
as    O
well    O
as    O
the    O
purines    O
(    O
i.e.    O
,    O
uridine    O
,    O
Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
,    O
UDP-glucose    B-Nucleotide114964590
)    O
.    O

Studies    O
focusing    O
on    O
nerve    O
tissue    O
indicate    O
that    O
GPR17    O
is    O
:    O
a    O
)    O
highly    O
expressed    O
in    O
precursors    O
to    O
mature    O
oligodendrocytes    O
but    O
not    O
expressed    O
in    O
mature    O
oligodendrocytes    O
,    O
suggesting    O
that    O
GPR17    O
must    O
be    O
down    O
-    O
regulated    O
in    O
order    O
for    O
precursor    O
cells    O
to    O
proceed    O
to    O
terminal    O
oligodendrocyte    O
differentiation    O
;    O
b    O
)    O
activated    O
by    O
uridine    O
,    O
Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
and    O
UDP-glucose    B-Nucleotide114964590
to    O
stimulate    O
outward    O
K+    O
channels    O
and    O
the    O
aforementioned    O
maturation    O
responses    O
in    O
oligodenrocyte    O
precursor    O
cells    O
;    O
c    O
)    O
also    O
activated    O
by    O
LTC4    O
and    O
LTD4    O
;    O
d    O
)    O
more    O
highly    O
expressed    O
in    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
tissues    O
of    O
animal    O
models    O
undergoing    O
ischemia    O
,    O
Experimental    O
autoimmune    O
encephalomyelitis    O
,    O
and    O
focal    O
demyelination    O
as    O
well    O
as    O
in    O
the    O
CNS    O
tissues    O
of    O
humans    O
suffering    O
brain    O
damage    O
due    O
to    O
ischemia    O
,    O
trauma    O
,    O
and    O
multiple    O
sclerosis    O
;    O
e    O
)    O
expressed    O
in    O
injured    O
neurons    O
and    O
associated    O
with    O
the    O
rapid    O
death    O
and    O
clearance    O
of    O
these    O
neurons    O
in    O
a    O
model    O
of    O
mouse    O
spinal    O
cord    O
crush    O
injury    O
;    O
f    O
)    O
acts    O
to    O
reduce    O
the    O
extent    O
of    O
spinal    O
cord    O
injury    O
in    O
the    O
latter    O
model    O
based    O
on    O
the    O
increased    O
extent    O
of    O
injury    O
in    O
GPR17-depleted    O
mice    O
;    O
and    O
g    O
)    O
acts    O
to    O
reduce    O
inflammation    O
,    O
elevate    O
hippocampus    O
neurogenesis    O
,    O
and    O
improve    O
learning    O
and    O
memory    O
in    O
a    O
rat    O
model    O
of    O
age    O
-    O
related    O
cognitive    O
impairment    O
based    O
on    O
the    O
effects    O
of    O
the    O
GPR17    O
antagonist    O
,    O
montelukast    O
,    O
as    O
well    O
as    O
of    O
GPR17    O
depletion    O
.    O

Once    O
the    O
incoming    O
galactose    O
has    O
been    O
converted    O
into    O
galactose    O
1-phosphate    O
(    O
Gal-1-P    O
)    O
,    O
it    O
is    O
involved    O
in    O
a    O
reaction    O
with    O
UDP-glucose    B-Nucleotide114964590
,    O
a    O
glucose    O
molecule    O
bonded    O
to    O
uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
.    O

Energy    O
for    O
glycogen    O
synthesis    O
comes    O
from    O
uridine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
UTP    O
)    O
,    O
which    O
reacts    O
with    O
glucose-1-phosphate    O
,    O
forming    O
UDP-glucose    B-Nucleotide114964590
,    O
in    O
a    O
reaction    O
catalysed    O
by    O
UTP—    O

Glycogen    O
is    O
synthesized    O
from    O
monomers    O
of    O
UDP-glucose    B-Nucleotide114964590
initially    O
by    O
the    O
protein    O
glycogenin    O
,    O
which    O
has    O
two    O
tyrosine    O
anchors    O
for    O
the    O
reducing    O
end    O
of    O
glycogen    O
,    O
since    O
glycogenin    O
is    O
a    O
homodimer    O
.    O

UDP-glucose    B-Nucleotide114964590
enters    O
the    O
synthesis    O
of    O
glycogen    O
.    O

Before    O
glucose    O
can    O
be    O
stored    O
as    O
glycogen    O
in    O
the    O
liver    O
and    O
muscles    O
,    O
the    O
enzyme    O
UDP    O
-    O
glucose    O
pyrophosphorylase    O
forms    O
a    O
UDP-glucose    B-Nucleotide114964590
unit    O
by    O
combining    O
glucose    O
1-phosphate    O
with    O
uridine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
,    O
cleaving    O
a    O
pyrophosphate    O
ion    O
in    O
the    O
process    O
.    O

It    O
is    O
made    O
from    O
UDP-glucose    B-Nucleotide114964590
by    O
UDP    O
-    O
glucose    O
6-dehydrogenase    O
(    O
EC    O
1.1.1.22    O
)    O
using    O
NAD+    O
as    O
a    O
cofactor    O
.    O

This    O
glucose-1-phosphate    O
can    O
then    O
react    O
with    O
UTP    B-Nucleotide114964590
to    O
yield    O
UDP-glucose    B-Nucleotide114964590
in    O
a    O
reaction    O
catalyzed    O
by    O
UDP    O
-    O
glucose    O
-    O
pyrophosphorylase    O
.    O

This    O
enzyme    O
performs    O
the    O
final    O
step    O
in    O
the    O
Leloir    O
pathway    O
of    O
galactose    O
metabolism    O
,    O
catalyzing    O
the    O
reversible    O
conversion    O
of    O
UDP-galactose    B-Nucleotide114964590
to    O
UDP-glucose    B-Nucleotide114964590
.    O

These    O
nucleotide    O
sugars    O
are    O
not    O
physiologically    O
favored    O
and    O
must    O
to    O
be    O
converted    O
from    O
UDP-glucose    B-Nucleotide114964590
and    O
Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
N-acetylglucosamine    I-Nucleotide114964590
(    O
GlcNAc    O
)    O
,    O
respectively    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
glycoprotein    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
glycoprotein    O
6-(D    O
-    O
glucose-1-phospho)-D    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
and    O
UDP-galactose    B-Nucleotide114964590
.    O

Structure    O
of    O
3'-phosphoadenosine-5'-phosphosulfate    B-Nucleotide114964590
,    O
a    O
key    O
intermediate    O
in    O
the    O
sulfur    O
cycle    O
.    O

The    O
enzymes    O
reduce    O
adenosine-5'-phosphosulfate    B-Nucleotide114964590
by    O
nucleophilic    O
attack    O
to    O
produce    O
the    O
sulfite    O
product    O
.    O

Plants    O
are    O
able    O
to    O
reduce    O
APS    B-Nucleotide114964590
directly    O
to    O
sulfite    O
(    O
using    O
APS    O
reductase    O
)    O
without    O
phosphorylating    O
APS    O
to    O
PAPS    B-Nucleotide114964590
.    O

Adenosine    O
3',5'-bisphosphate    O
is    O
produced    O
as    O
a    O
product    O
of    O
sulfotransferase    O
enzymes    O
from    O
the    O
donation    O
of    O
a    O
sulfate    O
group    O
from    O
the    O
coenzyme    O
3'-phosphoadenosine-5'-phosphosulfate    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
sulfate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
adenylyl    B-Nucleotide114964590
sulfate    I-Nucleotide114964590
.    O

The    O
most    O
common    O
sulfo    O
group    O
donor    O
is    O
3'-phosphoadenosine-5'-phosphosulfate    B-Nucleotide114964590
(    O
PAPS    O
)    O
.    O

The    O
enzyme    O
adenylosuccinate    O
synthase    O
carries    O
out    O
the    O
reaction    O
by    O
the    O
addition    O
of    O
aspartate    O
to    O
IMP    O
and    O
requires    O
the    O
input    O
of    O
energy    O
from    O
a    O
phosphoanhydride    O
bond    O
in    O
the    O
form    O
of    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Nucleotide114964590
for    O
GTP    B-Nucleotide114964590
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    B-Nucleotide114964590
,    O
and    O
GTP    B-Nucleotide114964590
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
oxaloacetate    O
(    O
OAA    O
)    O
to    O
phosphoenolpyruvate    O
(    O
PEP    O
)    O
in    O
the    O
presence    O
of    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Nucleotide114964590
to    O
GDP    B-Nucleotide114964590
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

The    O
biosynthesis    O
of    O
molybdopterin    O
begins    O
with    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Nucleotide114964590
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Nucleotide114964590
from    O
another    O
phosphorylated    O
compound    O
.    O

Their    O
work    O
revealed    O
that    O
the    O
addition    O
of    O
guanine    O
,    O
such    O
as    O
in    O
the    O
molecule    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
,    O
to    O
dopamine    O
binding    O
sites    O
could    O
increase    O
the    O
binding    O
affinity    O
of    O
the    O
D4    O
dopamine    O
receptor    O
while    O
decreasing    O
the    O
binding    O
affinity    O
of    O
the    O
D2    O
dopamine    O
receptor    O
.    O

Kinesins    O
are    O
structurally    O
related    O
to    O
G    O
proteins    O
,    O
which    O
hydrolyze    O
GTP    B-Nucleotide114964590
instead    O
of    O
ATP    O
.    O

This    O
enables    O
EF    O
-    O
Tu    O
to    O
bind    O
to    O
a    O
new    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
molecule    O
,    O
release    O
EF    O
-    O
Ts    O
,    O
and    O
go    O
on    O
to    O
catalyze    O
another    O
aminoacyl    O
tRNA    O
addition    O
.    O

Aluminum    O
fluoride    O
complexes    O
are    O
used    O
to    O
study    O
the    O
mechanistic    O
aspects    O
of    O
phosphoryl    O
transfer    O
reactions    O
in    O
biology    O
,    O
which    O
are    O
of    O
fundamental    O
importance    O
to    O
cells    O
,    O
as    O
phosphoric    O
acid    O
anhydrides    O
such    O
as    O
ATP    O
and    O
GTP    B-Nucleotide114964590
control    O
most    O
of    O
the    O
reactions    O
involved    O
in    O
metabolism    O
,    O
growth    O
and    O
differentiation    O
.    O

Guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
,    O
an    O
organic    O
chemical    O
and    O
energy    O
carrier    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Nucleotide114964590
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Nucleotide114964590
)    O
.    O

Oxaloacetate    O
is    O
later    O
decarboxylated    O
and    O
phosphorylated    O
by    O
phosphoenolpyruvate    O
carboxykinase    O
and    O
becomes    O
2-phosphoenolpyruvate    O
using    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
as    O
phosphate    O
source    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    B-Nucleotide114964590
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Nucleotide114964590
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

Dock11    O
binds    O
and    O
activates    O
nucleotide    O
-    O
free    O
Cdc42    O
via    O
its    O
DHR2    O
domain    O
and    O
has    O
also    O
been    O
reported    O
to    O
mediate    O
positive    O
feedback    O
on    O
active    O
,    O
GTP    B-Nucleotide114964590
-    O
bound    O
Cdc42    O
,    O
although    O
this    O
interaction    O
required    O
a    O
small    O
N    O
-    O
terminal    O
region    O
of    O
Dock11    O
in    O
addition    O
to    O
the    O
DHR2    O
domain    O
.    O

Furthermore    O
,    O
if    O
the    O
bound    O
AdoCbl    O
accrues    O
oxidative    O
damage    O
during    O
normal    O
functioning    O
,    O
"    O
MMAA    O
"    O
protein    O
fosters    O
exchange    O
of    O
the    O
damaged    O
cofactor    O
for    O
a    O
new    O
AdoCbl    O
via    O
a    O
GTP    B-Nucleotide114964590
-    O
reliant    O
pathway    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Nucleotide114964590
for    O
GDP    B-Nucleotide114964590
bound    O
to    O
G-α    O
subunit    O
.    O

The    O
main    O
function    O
of    O
the    O
SEC23A    O
protein    O
is    O
to    O
hydrolyze    O
or    O
break    O
down    O
a    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
molecule    O
bound    O
to    O
the    O
SAR1A    O
protein    O
at    O
the    O
start    O
of    O
the    O
COPII    O
pathway    O
.    O

GTP    B-Nucleotide114964590
,    O
CTP    B-Nucleotide114964590
,    O
and    O
UTP    B-Nucleotide114964590
are    O
also    O
nucleotides    O
important    O
in    O
the    O
protein    O
synthesis    O
,    O
lipid    O
synthesis    O
,    O
and    O
carbohydrate    O
metabolism    O
,    O
respectively    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
beta    O
-    O
L    O
-    O
fucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
L    O
-    O
fucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
glucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GTP    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
AMP    O
and    O
guanosine    O
3'-diphosphate    O
5'-triphosphate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
GTP    B-Nucleotide114964590
,    O
and    O
two    O
products    O
,    O
diphosphate    O
and    O
P1,P4-bis(5'-guanosyl    O
)    O
tetraphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Nucleotide114964590
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP-mannose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
(    O
5')ppPur    O
-    O
mRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
G(5')pppPur    O
-    O
mRNA    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Nucleotide114964590
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

Every    O
"    O
turn    O
"    O
of    O
the    O
citric    O
acid    O
cycle    O
produces    O
two    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
one    O
equivalent    O
of    O
ATP    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
through    O
substrate    O
-    O
level    O
phosphorylation    O
catalyzed    O
by    O
succinyl    O
-    O
CoA    O
synthetase    O
,    O
three    O
molecules    O
of    O
NADH    O
,    O
and    O
one    O
equivalent    O
of    O
FADH2    B-Nucleotide114964590
.    O

GTP    B-Nucleotide114964590
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
4-diphosphocytidyl-2-C-methyl-D-erythritol    B-Nucleotide114964590
2-phosphate    I-Nucleotide114964590
(    O
CDP    O
-    O
MEP    O
)    O
,    O
and    O
two    O
products    O
,    O
2-C    O
-    O
methyl    O
-    O
D    O
-    O
erythritol    O
2,4-cyclodiphosphate    O
(    O
MEcPP    O
)    O
and    O
CMP    B-Nucleotide114964590
.    O

Cytidine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
,    O
abbreviated    O
CDP    B-Nucleotide114964590
,    O
is    O
a    O
nucleoside    O
diphosphate    O
.    O

They    O
are    O
synthesized    O
by    O
the    O
addition    O
of    O
cytidine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
-    O
ethanolamine    O
to    O
diglycerides    O
,    O
releasing    O
cytidine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
.    O

Thymidine    O
can    O
be    O
phosphorylated    O
with    O
up    O
to    O
three    O
phosphoric    O
acid    O
groups    O
,    O
producing    O
dTMP    B-Nucleotide114964590
(    O
deoxythymidine    O
monophosphate    O
)    O
,    O
dTDP    B-Nucleotide114964590
,    O
or    O
dTTP    B-Nucleotide114964590
(    O
for    O
the    O
di-    O
and    O
tri-    O
phosphates    O
,    O
respectively    O
)    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
,    O
dGMP    O
,    O
and    O
dTMP    B-Nucleotide114964590
,    O
whereas    O
its    O
3    O
products    O
are    O
ADP    O
,    O
dGDP    O
,    O
and    O
dTDP    B-Nucleotide114964590
.    O

Upon    O
pathway    O
activation    O
,    O
HINT1    O
is    O
released    O
from    O
MITF    O
by    O
diadenosine    B-Nucleotide114964590
tetraphosphate    I-Nucleotide114964590
(    O
Ap4A    O
)    O
,    O
produced    O
by    O
LysRS    O
.    O

The    O
enzyme    O
is    O
reported    O
to    O
harbor    O
high    O
sequence    O
and    O
structural    O
similarity    O
to    O
the    O
Old    O
Yellow    O
Enzyme    O
,    O
a    O
large    O
group    O
of    O
flavin    B-Nucleotide114964590
-    O
dependent    O
redox    O
biocatalysts    O
of    O
yeast    O
species    O
,    O
and    O
an    O
oestrogen    O
-    O
binding    O
protein    O
of    O
"    O
Candida    O
albicans    O
"    O
.    O

The    O
residue    O
Arg-238    O
contributes    O
to    O
a    O
key    O
interaction    O
with    O
the    O
flavin    B-Nucleotide114964590
as    O
the    O
side    O
chain    O
of    O
this    O
group    O
is    O
located    O
close    O
to    O
the    O
N-1/C-2    O
carbonyl    O
region    O
of    O
the    O
flavin    O
isoalloxazine    O
ring    O
,    O
stabilizing    O
the    O
negative    O
charge    O
developed    O
during    O
enzyme    O
reduction    O
.    O

Flavin    B-Nucleotide114964590

The    O
active    O
site    O
of    O
the    O
flavoprotein    O
subunit    O
contains    O
a    O
catalytically    O
important    O
disulfide    O
bridge    O
located    O
above    O
the    O
pyrimidine    O
portion    O
of    O
the    O
flavin    B-Nucleotide114964590
ring    O
.    O

Flavoprotein    O
monooxygenase    O
form    O
flavin    B-Nucleotide114964590
hydroperoxides    O
at    O
the    O
enzyme    O
active    O
site    O
,    O
which    O
then    O
transfer    O
the    O
terminal    O
oxygen    O
atom    O
of    O
the    O
hydroperoxide    O
to    O
the    O
substrate    O
.    O

Squalene    O
monooxygenase    O
contains    O
a    O
loosely    O
bound    O
FAD    B-Nucleotide114964590
flavin    B-Nucleotide114964590
and    O
obtains    O
electrons    O
from    O
NADPH    O
-    O
cytochrome    O
P450    O
reductase    O
,    O
rather    O
than    O
binding    O
the    O
nicotinamide    O
cofactor    O
NADPH    O
directly    O
.    O

Many    O
flavin    B-Nucleotide114964590
-    O
dependent    O
enzymes    O
are    O
capable    O
of    O
oxidizing    O
aliphatic    O
nitro    O
compounds    O
to    O
less    O
-    O
toxic    O
aldehydes    O
and    O
ketones    O
.    O

"    O
Sulfolobus    O
metallicus    O
"    O
has    O
a    O
unique    O
type    O
II    O
NADH    O
dehydrogenase    O
with    O
no    O
iron    O
-    O
sulfur    O
clusters    O
that    O
is    O
covalently    O
linked    O
to    O
a    O
flavin    B-Nucleotide114964590
molecule    O
.    O

During    O
the    O
early    O
period    O
of    O
his    O
career    O
he    O
studied    O
-    O
together    O
with    O
István    O
Went    O
-    O
antibodies    O
and    O
flavins    B-Nucleotide114964590
,    O
on    O
the    O
ground    O
of    O
their    O
researches    O
they    O
could    O
successfully    O
produce    O
immunizer    O
pharmaceutical    O
drugs    O
used    O
as    O
treatment    O
for    O
allergies    O
.    O

He    O
is    O
best    O
known    O
for    O
his    O
development    O
of    O
rapid    O
-    O
reaction    O
techniques    O
,    O
including    O
stopped    O
flow    O
and    O
rapid    O
freeze    O
-    O
quench    O
EPR    O
methods    O
,    O
as    O
tools    O
to    O
study    O
the    O
mechanisms    O
of    O
enzymes    O
containing    O
flavin    B-Nucleotide114964590
,    O
iron    O
,    O
cobalamin    O
,    O
or    O
pyridoxal    O
phosphate    O
cofactors    O
.    O

Flavin    O
-    O
containing    O
amine    O
oxidoreductases    O
are    O
a    O
family    O
of    O
various    O
amine    O
oxidases    O
,    O
including    O
maize    O
polyamine    O
oxidase    O
(    O
PAO    O
)    O
,    O
L    O
-    O
amino    O
acid    O
oxidases    O
(    O
LAO    O
)    O
and    O
various    O
flavin    B-Nucleotide114964590
containing    O
monoamine    O
oxidases    O
(    O
MAO    O
)    O
.    O

Every    O
"    O
turn    O
"    O
of    O
the    O
citric    O
acid    O
cycle    O
produces    O
two    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
one    O
equivalent    O
of    O
ATP    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP    O
)    O
through    O
substrate    O
-    O
level    O
phosphorylation    O
catalyzed    O
by    O
succinyl    O
-    O
CoA    O
synthetase    O
,    O
three    O
molecules    O
of    O
NADH    O
,    O
and    O
one    O
equivalent    O
of    O
FADH2    B-Nucleotide114964590
.    O

It    O
is    O
a    O
flavin    B-Nucleotide114964590
derivative    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
dAMP    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
dADP    B-Nucleotide114964590
.    O

Cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
.    O

They    O
serve    O
as    O
sources    O
of    O
chemical    O
energy    O
(    O
adenosine    O
triphosphate    O
and    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
)    O
,    O
participate    O
in    O
cellular    O
signaling    O
(    O
cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
and    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
)    O
,    O
and    O
are    O
incorporated    O
into    O
important    O
cofactors    O
of    O
enzymatic    O
reactions    O
(    O
coenzyme    O
A    O
,    O
flavin    B-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
,    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
,    O
and    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
)    O
.    O

These    O
drugs    O
,    O
including    O
sildenafil    O
,    O
inhibit    O
the    O
action    O
of    O
the    O
phosphodiesterase    O
,    O
allowing    O
for    O
a    O
higher    O
concentration    O
of    O
cyclic    B-Nucleotide114964590
GMP    I-Nucleotide114964590
in    O
the    O
penis    O
when    O
it    O
is    O
physically    O
stimulated    O
.    O

This    O
response    O
is    O
mediated    O
by    O
the    O
release    O
of    O
nitric    O
oxide    O
(    O
NO    O
)    O
from    O
nerve    O
terminals    O
and    O
endothelial    O
cells    O
,    O
which    O
stimulates    O
the    O
synthesis    O
of    O
cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
more    O
commonly    O
known    O
as    O
cyclic    O
GMP    O
or    O
cGMP    O
)    O
in    O
smooth    O
muscle    O
cells    O
.    O

Transducin    O
removes    O
the    O
inhibition    O
from    O
cGMP    B-Nucleotide114964590
Phosphodiesterase    O
,    O
which    O
leads    O
to    O
the    O
breakdown    O
of    O
cGMP    O
.    O

cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590

In    O
addition    O
Dithranol    O
may    O
act    O
by    O
reducing    O
the    O
elevated    O
levels    O
of    O
cGMP    B-Nucleotide114964590
that    O
occurs    O
in    O
psoriasis    O
.    O

It    O
is    O
believed    O
that    O
the    O
core    O
contains    O
common    O
structural    O
elements    O
that    O
are    O
important    O
for    O
the    O
hydrolysis    O
of    O
cAMP    B-Nucleotide114964590
and    O
cGMP    B-Nucleotide114964590
phosphodiester    O
bonds    O
.    O

At    O
first    O
,    O
the    O
PDE3s    O
were    O
purified    O
and    O
described    O
as    O
enzymes    O
that    O
hydrolyse    O
both    O
cGMP    B-Nucleotide114964590
and    O
cAMP    B-Nucleotide114964590
with    O
Km    O
values    O
between    O
0.1    O
–    O
0.8    O
µM.    O
However    O
the    O
Vmax    O
for    O
cAMP    B-Nucleotide114964590
hydrolysis    O
is    O
4    O
–    O
10    O
times    O
higher    O
than    O
Vmax    O
for    O
cGMP    B-Nucleotide114964590
hydrolysis    O
.    O

Hydrolysis    O
of    O
cAMP    B-Nucleotide114964590
by    O
PDE3    O
isoforms    O
is    O
also    O
directly    O
inhibited    O
by    O
cGMP    B-Nucleotide114964590
,    O
although    O
PDE3B    O
is    O
only    O
≈10%    O
as    O
sensitive    O
to    O
cGMP    B-Nucleotide114964590
inhibition    O
as    O
PDE3A.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
and    O
cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Nucleotide114964590
and    O
cGMP    B-Nucleotide114964590
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
’s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Nucleotide114964590
or    O
cGMP    B-Nucleotide114964590
.    O

Sodium    O
nitroprusside    O
and    O
nitroglycerin    O
function    O
by    O
causing    O
vasodilation    O
through    O
nitric    O
oxide    O
,    O
which    O
manipulates    O
cGMP    B-Nucleotide114964590
levels    O
through    O
guanylate    O
cyclase    O
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Nucleotide114964590
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Nucleotide114964590
and    O
2-C    O
-    O
methyl    O
-    O
D    O
-    O
erythritol    O
4-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
4-diphosphocytidyl-2-C-methylerythritol    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dTTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyrophosphate    O
and    O
dTDP-glucose    B-Nucleotide114964590
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
UDP-glucuronate    B-Nucleotide114964590
,    O
and    O
one    O
product    O
,    O
UDP    O
-    O
D    O
-    O
galacturonate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
UDP-glucuronate    B-Nucleotide114964590
,    O
and    O
one    O
product    O
,    O
UDP    O
-    O
L    O
-    O
iduronate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
1-phospho    O
-    O
alpha    O
-    O
D    O
-    O
glucuronate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP-glucuronate    B-Nucleotide114964590
.    O

RelA    O
converts    O
GTP    B-Nucleotide114964590
and    O
ATP    O
into    O
pppGpp    B-Nucleotide114964590
by    O
adding    O
the    O
pyrophosphate    O
from    O
ATP    O
onto    O
the    O
3    O
'    O
carbon    O
of    O
the    O
ribose    O
in    O
GTP    O
,    O
releasing    O
AMP    O
.    O

pppGpp    O
is    O
converted    O
to    O
ppGpp    B-Nucleotide114964590
by    O
the    O
"    O
gpp    O
"    O
gene    O
product    O
,    O
releasing    O
Pi    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
glycoprotein    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
glycoprotein    O
6-(D    O
-    O
glucose-1-phospho)-D    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
UMP    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UDP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-galactose    B-Nucleotide114964590
and    O
undecaprenyl    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactosyl    O
-    O
diphosphoundecaprenol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
uridine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UMP    B-Nucleotide114964590
.    O

The    O
transferase    O
UDP    O
-    O
glucuronate    O
pyrophosphorylase    O
removes    O
a    O
UMP    B-Nucleotide114964590
and    O
glucuronokinase    O
,    O
with    O
the    O
cofactor    O
ADP    O
,    O
removes    O
the    O
final    O
phosphate    O
leading    O
to    O
D    O
-    O
glucuronic    O
acid    O
.    O

At    O
the    O
beginning    O
,    O
MS    O
-    O
SnuPE    O
relied    O
on    O
radioactive    O
ddNTP    B-Nucleotide114964590
as    O
the    O
reporter    O
of    O
the    O
primer    O
extension    O
.    O

database    O
search    O
-    O
degeneracy    O
(    O
biology    O
)    O
-    O
deletion    O
-    O
denaturation    O
-    O
denaturing    O
gel    O
-    O
deoxyribonuclease    O
(    O
DNase    O
)    O
-    O
deoxyribonucleic    O
acid    O
-    O
deoxyribonucleotide    B-Nucleotide114964590
-    O
diabetes    O
mellitus    O
-    O
dideoxy    O
sequencing    O
-    O
dideoxyribonucleotide    B-Nucleotide114964590
-    O
diploid    O
-    O
direct    O
repeat    O
-    O
DNA    O
ligase    O
-DNA    O
Bank    O
-    O
DNA    O
polymerase    O
-    O
DNA    O
replication    O
-    O
DNA    O
sequencing    O
-    O
DNase    O
-    O
dominant    O
-    O
dot    O
blot    O
-    O
double    O
helix    O
-    O
downstream    O
(    O
DNA    O
)    O
-    O
downstream    O
(    O
transduction    O
)    O
-    O
ds    O
-    O
duplex    O
-    O

NOSs    O
can    O
be    O
dimeric    O
,    O
calmodulin    O
-    O
dependent    O
or    O
calmodulin    O
-    O
containing    O
cytochrome    O
p450-like    O
hemoprotein    O
that    O
combines    O
reductase    O
and    O
oxygenase    O
catalytic    O
domains    O
in    O
one    O
dimer    O
,    O
bear    O
both    O
flavin    B-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
(    O
FAD    O
)    O
and    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
(    O
FMN    O
)    O
,    O
and    O
carry    O
out    O
a    O
5`-electron    O
oxidation    O
of    O
non    O
-    O
aromatic    O
amino    O
acid    O
arginine    O
with    O
the    O
aid    O
of    O
tetrahydrobiopterin    O
.    O

Phototropins    O
are    O
composed    O
of    O
two    O
LOV    O
domains    O
,    O
each    O
containing    O
a    O
non    O
-    O
covalently    O
bound    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
(    O
FMN    O
)    O
chromophore    O
in    O
its    O
dark    O
-    O
state    O
form    O
,    O
and    O
a    O
C    O
-    O
terminal    O
Ser    O
-    O
Thr    O
kinase    O
.    O

An    O
example    O
of    O
the    O
Rossmann    O
fold    O
,    O
a    O
structural    O
domain    O
of    O
a    O
decarboxylase    O
protein    O
from    O
the    O
bacterium    O
Staphylococcus    O
epidermidis    O
(    O
PDB    O
ID    O
1G5Q    O
)    O
with    O
the    O
bound    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
cofactor    O
shown    O
.    O

Luciferase    O
produces    O
blue    O
/    O
green    O
light    O
through    O
the    O
oxidation    O
of    O
reduced    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
and    O
a    O
long    O
-    O
chain    O
aldehyde    O
by    O
diatomic    O
oxygen    O
.    O

This    O
saturation    O
reaction    O
is    O
assisted    O
by    O
a    O
FMN    B-Nucleotide114964590
cofactor    I-Nucleotide114964590
and    O
the    O
enzyme    O
is    O
a    O
member    O
of    O
the    O
a    O
/    O
ß    O
-    O
barrel    O
flavoprotein    O
family    O
.    O

The    O
B    O
protein    O
is    O
a    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
(    O
FMN)-dependent    O
dehydrogenase    O
which    O
oxidizes    O
certain    O
azoline    O
rings    O
into    O
azoles    O
.    O

In    O
addition    O
to    O
NADPH    O
,    O
E.    O
Coli    O
DECR    O
requires    O
a    O
set    O
of    O
FAD    B-Nucleotide114964590
,    O
FMN    B-Nucleotide114964590
and    O
iron    O
-    O
sulfur    O
cluster    O
molecules    O
to    O
complete    O
the    O
electron    O
transfer    O
.    O

Flavodoxin    O
is    O
a    O
bacterial    O
protein    O
that    O
includes    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
.    O

It    O
can    O
emit    O
bluish    O
-    O
green    O
light    O
(    O
490    O
nm    O
)    O
due    O
to    O
a    O
chemical    O
reaction    O
between    O
FMN    B-Nucleotide114964590
,    O
luciferin    O
and    O
molecular    O
oxygen    O
catalysed    O
by    O
an    O
enzyme    O
called    O
luciferase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
riboflavin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
FMN    B-Nucleotide114964590
.    O

The    O
enzyme    O
contains    O
a    O
magnesium    O
binding    O
site    O
at    O
amino    O
acids    O
131    O
and    O
133    O
,    O
and    O
a    O
Flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
binding    O
site    O
at    O
amino    O
acids    O
188    O
and    O
195    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
and    O
riboflavin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
D    O
-    O
glucose    O
and    O
FMN    B-Nucleotide114964590
.    O

An    O
example    O
of    O
the    O
Rossmann    O
fold    O
,    O
a    O
structural    O
domain    O
of    O
a    O
decarboxylase    O
enzyme    O
from    O
the    O
bacterium    O
"    O
Staphylococcus    O
epidermidis    O
"    O
with    O
a    O
bound    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
cofactor    O
.    O

A    O
particularly    O
rich    O
natural    O
source    O
of    O
F420    O
is    O
"    O
Mycobacterium    O
smegmatis    O
"    O
,    O
in    O
which    O
several    O
dozen    O
enzymes    O
use    O
F420    O
instead    O
of    O
the    O
related    O
cofactor    O
FMN    B-Nucleotide114964590
used    O
by    O
homologous    O
enzymes    O
in    O
most    O
other    O
species    O
.    O

Then    O
m1G37    O
acts    O
as    O
a    O
substrate    O
for    O
the    O
enzyme    O
TYW1    O
and    O
forms    O
the    O
tricyclic    O
core    O
of    O
wybutosine    O
with    O
flavin    B-Nucleotide114964590
mononucleotide    I-Nucleotide114964590
(    O
FMN    O
)    O
as    O
a    O
cofactor    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dCTP    B-Nucleotide114964590
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
dCMP    O
and    O
diphosphate    O
.    O

For    O
example    O
,    O
enzyme    O
deoxyribonucleoside    O
triphosphate    O
pyrophosphatase    O
,    O
encoded    O
by    O
YJR069C    O
in    O
"    O
S.    O
cerevisiae    O
"    O
and    O
exhibiting    O
(    O
d)ITPase    O
and    O
(    O
d)XTPase    O
activities    O
,    O
hydrolyses    O
ITP    O
,    O
dITP    O
,    O
XTP    B-Nucleotide114964590
and    O
dXTP    O
releasing    O
pyrophosphate    O
and    O
IMP    B-Nucleotide114964590
,    O
dIMP    B-Nucleotide114964590
,    O
XMP    B-Nucleotide114964590
and    O
dXMP    O
,    O
respectively    O
.    O

The    O
nucleosides    O
each    O
contain    O
a    O
ribose    O
ring    O
,    O
one    O
with    O
adenine    O
attached    O
to    O
the    O
first    O
carbon    O
atom    O
(    O
the    O
1'    B-Nucleotide114964590
position    O
)    O
and    O
the    O
other    O
with    O
nicotinamide    O
at    O
this    O
position    O
.    O

Fluorescein    O
diacetate    O
hydrolysis    O
/    O
Propidium    B-Nucleotide114964590
iodide    I-Nucleotide114964590
staining    O
(    O
FDA    O
/    O
PI    O
staining    O
)    O

Propidium    B-Nucleotide114964590
iodide    I-Nucleotide114964590
,    O
DNA    O
stain    O
that    O
can    O
differentiate    O
necrotic    O
,    O
apoptotic    O
and    O
normal    O
cells    O
.    O

Physiological    O
agonist    O
:    O
Cyclic    B-Nucleotide114964590
ADP-ribose    I-Nucleotide114964590
can    O
act    O
as    O
a    O
physiological    O
gating    O
agent    O
.    O

NAD+    O
is    O
converted    O
into    O
cyclic    B-Nucleotide114964590
ADP    I-Nucleotide114964590
ribose    I-Nucleotide114964590
(    O
cADPR    O
)    O
,    O
a    O
second    O
messenger    O
which    O
interacts    O
with    O
ryanodine    O
receptors    O
(    O
RyR    O
)    O
on    O
the    O
surface    O
of    O
the    O
rough    O
endoplasmic    O
reticulum    O
.    O

In    O
addition    O
to    O
calmodulin    O
,    O
guanosine    O
5'-O-[gamma    O
-    O
thio]triphosphate    O
(    O
GTPgammaS    B-Nucleotide114964590
)    O
has    O
been    O
found    O
to    O
stimulate    O
PIMT    O
activity    O
.    O

Defined    O
by    O
their    O
mechanisms    O
,    O
two    O
main    O
classes    O
of    O
histone    O
demethylases    O
exist    O
:    O
a    O
flavin    B-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
(FAD)    I-Nucleotide114964590
amine    O
oxidase    O
,    O
and    O
an    O
Fe(II    O
)    O
and    O
α-ketoglutarate    O
-    O
dependent    O
dioxygenase    O
,    O
with    O
the    O
general    O
proposed    O
mechanisms    O
shown    O
in    O
the    O
figure    O
below    O
.    O

The    O
cry2    O
mutation    O
identified    O
in    O
position    O
260    O
(    O
A260    O
T    O
)    O
affects    O
the    O
cofactor    O
(    O
FAD    B-Nucleotide114964590
)    O
binding    O
domain    O
of    O
CRY2    O
.    O

In    O
functional    O
"    O
Neurospora    O
''    O
,    O
the    O
WC-1    O
LOV    O
domain    O
binds    O
to    O
the    O
flavin    B-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
(FAD)    I-Nucleotide114964590
chromophore    O
,    O
which    O
is    O
responsible    O
for    O
the    O
conversion    O
of    O
light    O
to    O
mechanical    O
energy    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    B-Nucleotide114964590
,    O
and    O
GTP    B-Nucleotide114964590
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

In    O
molecular    O
biology    O
,    O
the    O
FAD    O
dependent    O
oxidoreductase    O
family    O
of    O
proteins    O
is    O
a    O
family    O
of    O
FAD    B-Nucleotide114964590
dependent    O
oxidoreductases    O
.    O

In    O
addition    O
to    O
NADPH    O
,    O
E.    O
Coli    O
DECR    O
requires    O
a    O
set    O
of    O
FAD    B-Nucleotide114964590
,    O
FMN    B-Nucleotide114964590
and    O
iron    O
-    O
sulfur    O
cluster    O
molecules    O
to    O
complete    O
the    O
electron    O
transfer    O
.    O

Squalene    O
monooxygenase    O
contains    O
a    O
loosely    O
bound    O
FAD    B-Nucleotide114964590
flavin    B-Nucleotide114964590
and    O
obtains    O
electrons    O
from    O
NADPH    O
-    O
cytochrome    O
P450    O
reductase    O
,    O
rather    O
than    O
binding    O
the    O
nicotinamide    O
cofactor    O
NADPH    O
directly    O
.    O

It    O
was    O
discovered    O
by    O
J.G.    O
Hauge    O
as    O
the    O
third    O
redox    O
cofactor    O
after    O
nicotinamide    O
and    O
flavin    B-Nucleotide114964590
in    O
bacteria    O
(    O
although    O
he    O
hypothesised    O
that    O
it    O
was    O
naphthoquinone    O
)    O
.    O

Cellular    O
respiration    O
(    O
both    O
aerobic    O
and    O
anaerobic    O
)    O
utilizes    O
highly    O
reduced    O
chemical    O
compounds    O
such    O
as    O
NADH    O
and    O
FADH2    B-Nucleotide114964590
(    O
for    O
example    O
produced    O
during    O
glycolysis    O
and    O
the    O
citric    O
acid    O
cycle    O
)    O
to    O
establish    O
an    O
electrochemical    O
gradient    O
(    O
often    O
a    O
proton    O
gradient    O
)    O
across    O
a    O
membrane    O
,    O
resulting    O
in    O
an    O
electrical    O
potential    O
or    O
ion    O
concentration    O
difference    O
across    O
the    O
membrane    O
.    O

Path    O
A    O
involved    O
a    O
nucleophilic    O
attack    O
on    O
the    O
coenzyme    O
FAD    B-Nucleotide114964590
,    O
while    O
path    O
B    O
involves    O
a    O
free    O
-    O
radical    O
intermediate    O
.    O

Initially    O
,    O
SDHA    O
oxidizes    O
succinate    O
via    O
deprotonation    O
at    O
the    O
FAD    B-Nucleotide114964590
binding    O
site    O
,    O
leaving    O
fumarate    O
,    O
loosely    O
bound    O
to    O
the    O
active    O
site    O
,    O
free    O
to    O
exit    O
the    O
protein    O
.    O

Initially    O
,    O
SDHA    O
oxidizes    O
succinate    O
via    O
deprotonation    O
at    O
the    O
FAD    B-Nucleotide114964590
binding    O
site    O
,    O
forming    O
FADH2    B-Nucleotide114964590
and    O
leaving    O
fumarate    O
,    O
loosely    O
bound    O
to    O
the    O
active    O
site    O
,    O
free    O
to    O
exit    O
the    O
protein    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
FAD    B-Nucleotide114964590
,    O
and    O
two    O
products    O
,    O
AMP    O
and    O
riboflavin    O
cyclic-4',5'-phosphate    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    B-Nucleotide114964590
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Nucleotide114964590
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
5,10-methylenetetrahydrofolate    O
,    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
and    O
FADH2    B-Nucleotide114964590
,    O
whereas    O
its    O
3    O
products    O
are    O
tetrahydrofolate    O
,    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
,    O
and    O
FAD    B-Nucleotide114964590
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
5,10-methylenetetrahydrofolate    O
,    O
dUMP    B-Nucleotide114964590
,    O
and    O
FADH2    B-Nucleotide114964590
,    O
whereas    O
its    O
3    O
products    O
are    O
dTMP    B-Nucleotide114964590
,    O
tetrahydrofolate    O
,    O
and    O
FAD    B-Nucleotide114964590
.    O

The    O
flavin    B-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
(    O
FAD    O
)    O
is    O
located    O
at    O
the    O
junction    O
between    O
the    O
middle    O
beta    O
-    O
strand    O
and    O
the    O
carboxyl    O
terminal    O
alpha    O
-    O
helix    O
domain    O
of    O
one    O
subunit    O
and    O
the    O
carboxyl    O
-    O
terminal    O
domain    O
of    O
the    O
neighboring    O
subunit    O
.    O

Flavoprotein    O
pyridine    O
nucleotide    O
cytochrome    O
reductases    O
catalyse    O
the    O
interchange    O
of    O
reducing    O
equivalents    O
between    O
one    O
-    O
electron    O
carriers    O
and    O
the    O
two    O
-    O
electron    O
-    O
carrying    O
nicotinamide    B-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
.    O

The    O
products    O
of    O
this    O
process    O
are    O
carbon    O
dioxide    O
and    O
water    O
,    O
but    O
the    O
energy    O
transferred    O
is    O
used    O
to    O
break    O
bonds    O
in    O
ADP    O
as    O
the    O
third    O
phosphate    O
group    O
is    O
added    O
to    O
form    O
ATP    O
(    O
adenosine    O
triphosphate    O
)    O
,    O
by    O
substrate    O
-    O
level    O
phosphorylation    O
,    O
NADH    O
and    O
FADH2    B-Nucleotide114964590

In    O
oxidation    O
,    O
the    O
electrons    O
are    O
stripped    O
from    O
a    O
glucose    O
molecule    O
to    O
reduce    O
NAD+    O
and    O
FAD    B-Nucleotide114964590
.    O

Each    O
monomer    O
contains    O
a    O
FAD    B-Nucleotide114964590
prosthetic    O
group    O
,    O
a    O
NADPH    O
binding    O
domain    O
,    O
and    O
an    O
active    O
site    O
containing    O
a    O
redox    O
-    O
active    O
disulfide    O
bond    O
.    O

E.    O
coli    O
:    O
In    O
"    O
E.    O
coli    O
"    O
ThxR    O
there    O
are    O
two    O
binding    O
domains    O
,    O
one    O
for    O
FAD    B-Nucleotide114964590
and    O
another    O
for    O
NADPH    O
.    O

It    O
contains    O
a    O
FAD    B-Nucleotide114964590
and    O
NADPH    O
binding    O
domain    O
,    O
and    O
an    O
interface    O
between    O
two    O
monomer    O
subunits    O
.    O

In    O
mammalian    O
ThxR    O
there    O
is    O
an    O
insertion    O
in    O
the    O
FAD    B-Nucleotide114964590
binding    O
domain    O
between    O
two    O
alpha    O
helices    O
which    O
forms    O
a    O
small    O
pair    O
of    O
beta    O
strands    O
.    O

The    O
active    O
disulfide    O
in    O
the    O
enzyme    O
is    O
located    O
on    O
one    O
of    O
these    O
helices    O
and    O
thus    O
the    O
active    O
disulfide    O
bond    O
is    O
located    O
in    O
the    O
FAD    B-Nucleotide114964590
domain    O
and    O
not    O
the    O
NADPH    O
domain    O
as    O
in    O
"    O
E.    O
coli    O
"    O
and    O
other    O
prokaryotes    O
.    O

NADH    O
and    O
FADH2    O
are    O
recycled    O
to    O
(    O
NAD+    O
and    O
FAD    B-Nucleotide114964590
,    O
respectively    O
)    O
,    O
generating    O
additional    O
ATP    O
by    O
oxidative    O
phosphorylation    O
.    O

Electron    O
transport    O
chain    O
–    O
a    O
biochemical    O
process    O
which    O
associates    O
electron    O
carriers    O
(    O
such    O
as    O
NADH    O
and    O
FADH2    B-Nucleotide114964590
)    O
and    O
mediating    O
biochemical    O
reactions    O
that    O
produce    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
,    O
which    O
is    O
a    O
major    O
energy    O
intermediate    O
in    O
living    O
organisms    O
.    O

Electron    O
transport    O
chain    O
–    O
A    O
biochemical    O
process    O
which    O
associates    O
electron    O
carriers    O
(    O
such    O
as    O
NADH    O
and    O
FADH2    B-Nucleotide114964590
)    O
and    O
mediating    O
biochemical    O
reactions    O
that    O
produce    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
,    O
which    O
is    O
a    O
major    O
energy    O
intermediate    O
in    O
living    O
organisms    O
.    O

AO    O
is    O
a    O
homodimer    O
,    O
and    O
requires    O
FAD    B-Nucleotide114964590
,    O
molybdenum    O
(    O
MoCo    O
)    O
and    O
two    O
2FE-2S    O
clusters    O
as    O
cofactors    O
.    O

Mitochondrial    O
glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD2    O
)    O
,    O
catalyzes    O
the    O
irreversible    O
oxidation    O
of    O
glycerol-3-phosphate    O
to    O
dihydroxyacetone    O
phosphate    O
and    O
concomitantly    O
transfers    O
two    O
electrons    O
from    O
FAD    B-Nucleotide114964590
to    O
the    O
electron    O
transport    O
chain    O
.    O

Once    O
the    O
glycerol-3-phosphate    O
has    O
moved    O
through    O
the    O
inner    O
mitochondrial    O
membrane    O
it    O
can    O
then    O
be    O
oxidised    O
by    O
a    O
separate    O
isoform    O
of    O
glycerol-3-phosphate    O
dehydrogenase    O
that    O
uses    O
quinone    O
as    O
an    O
oxidant    O
and    O
FAD    B-Nucleotide114964590
as    O
a    O
co    O
-    O
factor    O
.    O

GPDH    O
-    O
M    O
in    O
addition    O
uses    O
FAD    B-Nucleotide114964590
as    O
a    O
co    O
-    O
factor    O
.    O

Calcium    B-Nucleotide114964590
inosinate    I-Nucleotide114964590
,    O
a    O
food    O
additive    O

STING    O
has    O
been    O
shown    O
to    O
bind    O
directly    O
to    O
cyclic    B-Nucleotide114964590
di-GMP    I-Nucleotide114964590
,    O
and    O
this    O
recognition    O
leads    O
to    O
the    O
production    O
of    O
cytokines    O
,    O
such    O
as    O
type    O
I    O
interferon    O
,    O
that    O
are    O
essential    O
for    O
successful    O
pathogen    O
elimination    O
.    O

Some    O
motility    O
regulatory    O
linkages    O
that    O
H    O
-    O
NS    O
influences    O
include    O
the    O
messenger    O
molecule    O
Cyclic    B-Nucleotide114964590
di-GMP    I-Nucleotide114964590
,    O
the    O
bio    O
-    O
film    O
regulatory    O
protein    O
CsgD    O
,    O
and    O
the    O
sigma    O
factors    O
,    O
σ(S    O
)    O
and    O
σ(F    O
)    O
.    O

The    O
5    O
'    O
flanking    O
region    O
is    O
a    O
region    O
of    O
DNA    O
that    O
is    O
adjacent    O
to    O
the    O
5'    B-Nucleotide114964590
end    I-Nucleotide114964590
of    O
the    O
gene    O
.    O

fission    O
yeast    O
exo1    O
,    O
a    O
-3'    B-Nucleotide114964590
double    O
-    O
stranded    O
DNA    O
exonuclease    O
that    O
may    O
act    O
in    O
a    O
pathway    O
that    O
corrects    O
mismatched    O
base    O
pairs    O
;    O

It    O
is    O
located    O
at    O
the    O
5'    B-Nucleotide114964590
end    O
of    O
the    O
ureB    O
gene    O
in    O
the    O
urease    O
gene    O
cluster    O
,    O
and    O
is    O
antisense    O
to    O
ureB.    O
Its    O
expression    O
is    O
regulated    O
by    O
the    O
arsS    O
/    O
arsR    O
two    O
-    O
component    O
regulatory    O
system    O
,    O
arsS    O
downregulates    O
5    O
'    O
ureB    O
sRNA    O
expression    O
under    O
acidic    O
conditions    O
leading    O
to    O
an    O
increase    O
in    O
ureB    O
expression    O
.    O

In    O
short    O
,    O
Rho    O
factor    O
acts    O
as    O
an    O
ATP    O
-    O
dependent    O
unwinding    O
enzyme    O
,    O
moving    O
along    O
the    O
newly    O
forming    O
RNA    O
molecule    O
towards    O
its    O
3′    B-Nucleotide114964590
end    I-Nucleotide114964590
and    O
unwinding    O
it    O
from    O
the    O
DNA    O
template    O
as    O
it    O
proceeds    O
.    O

The    O
Artemis    O
protein    O
has    O
single    O
-    O
strand    O
-    O
specific    O
5'    B-Nucleotide114964590
to    I-Nucleotide114964590
3'    I-Nucleotide114964590
exonuclease    O
activity    O
,    O
but    O
it    O
can    O
also    O
complex    O
with    O
the    O
469    O
kDa    O
DNA    O
-    O
dependent    O
protein    O
kinase    O
(    O
DNA    O
-    O
PKcs    O
)    O
to    O
gain    O
endonuclease    O
activity    O
on    O
hairpins    O
and    O
the    O
and    O
overhangs    O
;    O
the    O
DNA    O
-    O
PKcs    O
phosphorylates    O
Artemis    O
to    O
give    O
it    O
this    O
new    O
function    O
.    O

CpG    O
islands    O
are    O
generally    O
200    O
to    O
2000    O
base    O
pairs    O
long    O
,    O
have    O
a    O
C    O
:    O
G    O
base    O
pair    O
content    O
>    O
50%    O
,    O
and    O
have    O
regions    O
of    O
DNA    O
where    O
a    O
cytosine    O
nucleotide    O
is    O
followed    O
by    O
a    O
guanine    O
nucleotide    O
and    O
this    O
occurs    O
frequently    O
in    O
the    O
linear    O
sequence    O
of    O
bases    O
along    O
its    O
5'    B-Nucleotide114964590
→    I-Nucleotide114964590
3'    I-Nucleotide114964590
direction    I-Nucleotide114964590
.    O

Finally    O
,    O
RecBCD    O
enzyme    O
(    O
perhaps    O
the    O
RecC    O
subunit    O
)    O
recognizes    O
a    O
specific    O
sequence    O
in    O
DNA    O
,    O
5'    B-Nucleotide114964590
3'    B-Nucleotide114964590
,    O
known    O
as    O
Chi    O
(    O
sometimes    O
designated    O
with    O
the    O
Greek    O
letter    O
χ    O
)    O
.    O

Tat    O
acts    O
by    O
binding    O
to    O
an    O
RNA    O
stem    O
-    O
loop    O
structure    O
,    O
the    O
trans    O
-    O
activating    O
response    O
element    O
(    O
TAR    O
)    O
,    O
found    O
at    O
the    O
5′    B-Nucleotide114964590
ends    I-Nucleotide114964590
of    O
nascent    O
HIV-1    O
transcripts    O
.    O

It    O
is    O
an    O
RNA    O
structure    O
situated    O
near    O
the    O
5'    B-Nucleotide114964590
end    O
of    O
the    O
HBV    O
pregenomic    O
RNA    O
.    O

The    O
non    O
-    O
stop    O
decay    O
pathway    O
releases    O
ribosomes    O
that    O
have    O
reached    O
the    O
far    O
3'    B-Nucleotide114964590
end    I-Nucleotide114964590
of    O
an    O
mRNA    O
and    O
guides    O
the    O
mRNA    O
to    O
the    O
exosome    O
complex    O
,    O
or    O
to    O
RNase    O
R    O
in    O
bacteria    O
for    O
selective    O
degradation    O
.    O

Additional    O
processing    O
steps    O
attach    O
modifications    O
to    O
the    O
5'    B-Nucleotide114964590
and    O
3'    B-Nucleotide114964590
ends    O
of    O
eukaryotic    O
pre    O
-    O
mRNA    O
.    O

In    O
molecular    O
biology    O
,    O
the    O
PyrG    O
leader    O
is    O
a    O
"    O
cis    O
"-    O
regulatory    O
RNA    O
element    O
found    O
at    O
the    O
5'    B-Nucleotide114964590
of    O
the    O
PyrG    O
mRNA    O
.    O

In    O
molecular    O
biology    O
,    O
the    O
PyrC    O
leader    O
is    O
a    O
"    O
cis    O
"-    O
regulatory    O
RNA    O
element    O
found    O
at    O
the    O
5'    B-Nucleotide114964590
of    O
the    O
PyrC    O
mRNA    O
in    O
Enterobacteria    O
.    O

Directionality    B-Nucleotide114964590
,    O
in    O
molecular    O
biology    O
and    O
biochemistry    O
,    O
is    O
the    O
end    O
-    O
to    O
-    O
end    O
chemical    O
orientation    O
of    O
a    O
single    O
strand    O
of    O
nucleic    O
acid    O
.    O

In    O
a    O
single    O
strand    O
of    O
DNA    O
or    O
RNA    O
,    O
the    O
chemical    O
convention    O
of    O
naming    O
carbon    O
atoms    O
in    O
the    O
nucleotide    O
sugar    O
-    O
ring    O
means    O
that    O
there    O
will    O
be    O
a    O
5′    B-Nucleotide114964590
,    O
which    O
frequently    O
contains    O
a    O
phosphate    O
group    O
attached    O
to    O
the    O
5′    O
carbon    O
of    O
the    O
ribose    O
ring    O
,    O
and    O
a    O
3′    B-Nucleotide114964590
(    O
usually    O
pronounced    O
"    O
five    O
prime    O
end    O
"    O
and    O
"    O
three    O
prime    O
end    O
"    O
)    O
,    O
which    O
typically    O
is    O
unmodified    O
from    O
the    O
ribose    O
-OH    O
substituent    O
.    O

By    O
convention    O
,    O
sequences    O
are    O
usually    O
presented    O
from    O
the    O
5'    B-Nucleotide114964590
end    I-Nucleotide114964590
to    I-Nucleotide114964590
the    I-Nucleotide114964590
3'    I-Nucleotide114964590
end    I-Nucleotide114964590
.    O

In    O
the    O
typical    O
case    O
,    O
the    O
sequences    O
are    O
printed    O
abutting    O
one    O
another    O
without    O
gaps    O
,    O
as    O
in    O
the    O
sequence    O
AAAGTCTGAC    O
,    O
read    O
left    O
to    O
right    O
in    O
the    O
5'    B-Nucleotide114964590
to    I-Nucleotide114964590
3'    I-Nucleotide114964590
direction    O
.    O

The    O
gene    O
on    O
the    O
strand    O
complementary    O
to    O
FANCD2    O
located    O
5'    B-Nucleotide114964590
from    O
CYCSP11    O
and    O
3’    O
from    O
BRK1    O
and    O
VHL    O
genes    O
.    O

There    O
are    O
six    O
alternatively    O
spliced    O
transcripts    O
with    O
differences    O
in    O
the    O
5'    B-Nucleotide114964590
and    O
3    O
'    O
ends    O
as    O
well    O
changes    O
in    O
exon    O
usage    O
.    O

During    O
transcription    O
,    O
the    O
original    O
template    O
strand    O
is    O
usually    O
read    O
from    O
the    O
3'    B-Nucleotide114964590
to    O
the    O
5'    B-Nucleotide114964590
end    O
from    O
beginning    O
to    O
end    O
.    O

The    O
gene    O
encoding    O
HOTTIP    O
is    O
located    O
at    O
the    O
5'    B-Nucleotide114964590
tip    O
of    O
the    O
HOXA    O
locus    O
,    O
and    O
coordinates    O
the    O
activation    O
of    O
several    O
of    O
the    O
5    O
'    O
HOXA    O
genes    O
.    O

The    O
covalent    O
attachment    O
to    O
the    O
tRNA    O
3’    B-Nucleotide114964590
end    I-Nucleotide114964590
is    O
catalyzed    O
by    O
enzymes    O
called    O
aminoacyl    O
tRNA    O
synthetases    O
.    O

#    O
A    O
5'-terminal    B-Nucleotide114964590
phosphate    O
group    O
.    O

This    O
enzyme    O
is    O
responsible    O
for    O
the    O
addition    O
of    O
the    O
3'    B-Nucleotide114964590
polyadenine    O
tail    O
to    O
a    O
newly    O
synthesized    O
pre    O
-    O
messenger    O
RNA    O
(    O
pre    O
-    O
mRNA    O
)    O
molecule    O
during    O
the    O
process    O
of    O
gene    O
transcription    O
.    O

When    O
an    O
IRES    O
segment    O
is    O
located    O
between    O
two    O
reporter    O
open    O
reading    O
frames    O
in    O
a    O
eukaryotic    O
mRNA    O
molecule    O
(    O
a    O
bicistronic    O
mRNA    O
)    O
,    O
it    O
can    O
drive    O
translation    O
of    O
the    O
downstream    O
protein    O
coding    O
region    O
independently    O
of    O
the    O
5'-cap    O
structure    O
bound    O
to    O
the    O
5'    B-Nucleotide114964590
end    I-Nucleotide114964590
of    O
the    O
mRNA    O
molecule    O
.    O

3'    B-Nucleotide114964590
end    I-Nucleotide114964590
-    O
3'    B-Nucleotide114964590
flanking    I-Nucleotide114964590
region    I-Nucleotide114964590
-    O
5'    B-Nucleotide114964590
end    I-Nucleotide114964590
-    O
5    O
'    O
flanking    O
region    O
-    O
5'-ribose-    O
3    O
'    O
-    O

5-Methyluridine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
or    O
m5UTP    B-Nucleotide114964590
is    O
one    O
of    O
five    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
adenosine    B-Nucleotide114964590
3',5'-bisphosphate    I-Nucleotide114964590
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
adenosine    O
5'-phosphate    O
and    O
phosphate    O
.    O

The    O
encoded    O
protein    O
is    O
localized    O
to    O
the    O
Golgi    O
apparatus    O
and    O
catalyzes    O
the    O
hydrolysis    O
of    O
phosphoadenosine    B-Nucleotide114964590
phosphate    I-Nucleotide114964590
(    O
PAP    O
)    O
to    O
adenosine    O
monophosphate    O
(    O
AMP    O
)    O
.    O

Adenosine    B-Nucleotide114964590
3',5'-bisphosphate    I-Nucleotide114964590

Adenosine    B-Nucleotide114964590
3',5'-bisphosphate    I-Nucleotide114964590
is    O
a    O
form    O
of    O
an    O
adenosine    O
nucleotide    O
with    O
two    O
phosphate    O
groups    O
attached    O
to    O
different    O
carbons    O
in    O
the    O
ribose    O
ring    O
.    O

GMP    O
is    O
formed    O
by    O
the    O
inosinate    O
oxidation    O
to    O
xanthylate    B-Nucleotide114964590
(    O
XMP    O
)    O
,    O
and    O
afterwards    O
adds    O
an    O
amino    O
group    O
on    O
carbon    O
2    O
.    O

Xanthosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590

Xanthosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dTTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
dTDP    O
-    O
galactose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dTTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyrophosphate    O
and    O
dTDP-glucose    B-Nucleotide114964590
.    O

T7    O
DNA    O
helicase    O
is    O
a    O
hexameric    O
motor    O
protein    O
that    O
uses    O
energy    O
from    O
dTTP    B-Nucleotide114964590
hydrolysis    O
to    O
process    O
unidirectionally    O
along    O
single    O
stranded    O
DNA    O
,    O
separating    O
the    O
two    O
strands    O
as    O
it    O
progresses    O
.    O

Oligonucleotide    O
chips    O
are    O
microarrays    O
of    O
oligonucleotide    B-Nucleotide114964590
.    O

"    O
Probe    O
type    O
"    O
:    O
DNA    O
arrays    O
can    O
comprise    O
either    O
mechanically    O
spotted    O
cDNAs    O
or    O
PCR    O
-    O
products    O
,    O
mechanically    O
spotted    O
oligonucleotide    B-Nucleotide114964590
,    O
or    O
oligonucleotides    O
that    O
are    O
synthesized    O
"    O
in    O
situ    O
"    O
.    O

Oligonucleotide    O
microarrays    O
are    O
designed    O
using    O
pairs    O
of    O
oligonucleotide    B-Nucleotide114964590
hybridization    O
probes    O
targeting    O
CpG    O
sites    O
of    O
interest    O
.    O

A    O
notation    O
for    O
gas    O
-    O
phase    O
fragmentation    O
of    O
oligonucleotide    B-Nucleotide114964590
ions    O
has    O
been    O
proposed    O
.    O

There    O
are    O
currently    O
no    O
established    O
treatments    O
,    O
but    O
,    O
one    O
study    O
,    O
focused    O
on    O
myotonic    O
dystrophy    O
type    O
1    O
,    O
suggests    O
that    O
the    O
use    O
of    O
antisense    O
oligonucleotides    B-Nucleotide114964590
(    O
ASOs    O
)    O
known    O
as    O
gapmers    O
can    O
aid    O
in    O
decreasing    O
the    O
mutant    O
RNA    O
repeat    O
transcripts    O
.    O

Synthetic    O
biomolecules    O
such    O
as    O
oligonucleotides    B-Nucleotide114964590
may    O
also    O
be    O
used    O
as    O
analytes    O
.    O

Nusinersen    O
is    O
an    O
antisense    B-Nucleotide114964590
oligonucleotide    I-Nucleotide114964590
in    O
which    O
the    O
2’-hydroxy    O
groups    O
of    O
the    O
ribofuranosyl    O
rings    O
are    O
replaced    O
with    O
2’-"O"-2-methoxyethyl    O
groups    O
and    O
the    O
phosphate    O
linkages    O
are    O
replaced    O
with    O
phosphorothioate    O
linkages    O
.    O

Efficiently    O
generating    O
oligonucleotide    B-Nucleotide114964590
beyond    O
~110    O
nucleotides    O
in    O
length    O
is    O
very    O
difficult    O
,    O
so    O
to    O
insert    O
a    O
mutation    O
further    O
into    O
a    O
sequence    O
than    O
a    O
110    O
nt    O
primer    O
will    O
allow    O
,    O
it    O
is    O
necessary    O
to    O
employ    O
overlap    O
extension    O
PCR    O
.    O

The    O
genomic    O
signature    O
refers    O
to    O
the    O
characteristic    O
frequency    O
of    O
oligonucleotide    B-Nucleotide114964590
in    O
a    O
genome    O
or    O
sequence    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

According    O
to    O
preliminary    O
findings    O
of    O
a    O
novel    O
method    O
of    O
SGLT-2    O
inhibition    O
,    O
the    O
antisense    O
oligonucleotide    B-Nucleotide114964590
ISIS    O
388626    O
improved    O
plasma    O
glucose    O
in    O
rodents    O
and    O
dogs    O
by    O
reducing    O
mRNA    O
expression    O
in    O
the    O
proximal    O
renal    O
tubules    O
by    O
up    O
to    O
80%    O
if    O
it    O
was    O
given    O
once    O
a    O
week    O
.    O

In    O
2010    O
,    O
ISIS    O
Pharmaceuticals    O
recently    O
announced    O
that    O
ISIS    O
-    O
SGLT-2RX    O
,    O
which    O
is    O
a    O
12-nucleotide    O
antisense    O
oligonucleotide    B-Nucleotide114964590
,    O
was    O
about    O
to    O
commence    O
clinical    O
phase    O
1    O
studies    O
.    O

Oblimersen    O
(    O
INN    O
,    O
trade    O
name    O
Genasense    O
;    O
also    O
known    O
as    O
Augmerosen    O
and    O
bcl-2    O
antisense    O
oligodeoxynucleotide    O
G3139    O
)    O
is    O
an    O
antisense    O
oligodeoxyribonucleotide    B-Nucleotide114964590
being    O
studied    O
as    O
a    O
possible    O
treatment    O
for    O
several    O
types    O
of    O
cancer    O
,    O
including    O
chronic    O
lymphocytic    O
leukemia    O
,    O
B    O
-    O
cell    O
lymphoma    O
,    O
and    O
breast    O
cancer    O
.    O

An    O
antisense    O
oligonucleotide    B-Nucleotide114964590
drug    O
Genasense    O
(    O
G3139    O
)    O
has    O
been    O
developed    O
by    O
Genta    O
Incorporated    O
to    O
target    O
Bcl-2    O
.    O

oligo    B-Nucleotide114964590
-    O
oligodeoxyribonucleotide    B-Nucleotide114964590
-    O
oligonucleotide    B-Nucleotide114964590
-    O
oncogene    O
-    O
oncovirus    O
-    O
open    O
reading    O
frame    O
-    O
operator    O
-    O
operon    O
-    O
origin    O
of    O
replication    O
-    O

Acrydite    O
is    O
a    O
phosphoramidite    O
that    O
allows    O
the    O
synthesis    O
of    O
oligonucleotides    B-Nucleotide114964590
with    O
a    O
methacryl    O
group    O
at    O
the    O
5    O
'    O
end    O
(    O
less    O
commonly    O
3    O
'    O
or    O
internal    O
)    O
.    O

Mutational    O
analysis    O
and    O
studies    O
involving    O
complementary    O
oligonucleotide    B-Nucleotide114964590
demonstrate    O
that    O
the    O
stability    O
of    O
the    O
2–3    O
structure    O
corresponds    O
to    O
the    O
operon    O
expression    O
level    O
.    O

This    O
synthesized    O
nucleic    O
acid    O
is    O
termed    O
an    O
"    O
anti    O
-    O
sense    O
"    O
oligonucleotide    B-Nucleotide114964590
(    O
AON    O
)    O
because    O
its    O
base    O
sequence    O
is    O
complementary    O
to    O
the    O
gene    O
's    O
messenger    O
RNA    O
(    O
mRNA    O
)    O
,    O
which    O
is    O
called    O
the    O
"    O
sense    O
"    O
sequence    O
(    O
so    O
that    O
a    O
sense    O
segment    O
of    O
mRNA    O
"    O
5'-AAGGUC-3    O
'    O
"    O
would    O
be    O
blocked    O
by    O
the    O
anti    O
-    O
sense    O
mRNA    O
segment    O
"    O
3'-UUCCAG-5    O
'    O
")    O
.    O

Over    O
the    O
following    O
years    O
,    O
an    O
antisense    B-Nucleotide114964590
oligonucleotide    I-Nucleotide114964590
later    O
named    O
nusinersen    O
was    O
developed    O
by    O
Ionis    O
Pharmaceuticals    O
under    O
a    O
licensing    O
agreement    O
with    O
Biogen    O
.    O

Gene    O
Tools    O
,    O
LLC    O
is    O
a    O
limited    O
liability    O
company    O
located    O
in    O
Philomath    O
,    O
Oregon    O
,    O
United    O
States    O
that    O
manufactures    O
Morpholino    B-Nucleotide114964590
antisense    O
oligo    B-Nucleotide114964590
and    O
delivery    O
reagents    O
.    O

As    O
referred    O
to    O
as    O
the    O
rolling    O
circle    O
method    O
,    O
the    O
improvements    O
of    O
this    O
technique    O
stems    O
from    O
its    O
efficiency    O
in    O
synthesizing    O
RNA    O
oligonucleotide    B-Nucleotide114964590
.    O

Nanopore    O
sequencing    O
is    O
a    O
fourth    O
generation    O
approach    O
used    O
in    O
the    O
sequencing    O
of    O
biopolymers-    O
specifically    O
,    O
polynucleotide    B-Nucleotide114964590
in    O
the    O
form    O
of    O
DNA    O
or    O
RNA    O
.    O

It    O
is    O
used    O
to    O
insert    O
specific    O
mutations    O
at    O
specific    O
points    O
in    O
a    O
sequence    O
or    O
to    O
splice    O
smaller    O
DNA    O
fragments    O
into    O
a    O
larger    O
polynucleotide    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
3'-phosphopolynucleotide    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
polynucleotide    B-Nucleotide114964590
and    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
5'-phosphopolynucleotide    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
polynucleotide    B-Nucleotide114964590
and    O
phosphate    O
.    O

N-nucleotides    B-Nucleotide114964590
,    O
or    O
nontemplated    O
nucleotides    O
are    O
believed    O
to    O
exist    O
only    O
to    O
create    O
diversity    O
at    O
V(D)J    O
junctions    O
(    O
see    O
V(D)J    O
recombination    O
)    O
during    O
lymphocyte    O
development    O
.    O

Nicotinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
adenine    I-Nucleotide114964590
dinucleotide    I-Nucleotide114964590
phosphate    I-Nucleotide114964590
,    O
(    O
NAADP    B-Nucleotide114964590
)    O
,    O
is    O
a    O
Ca2    O
+    O
-mobilizing    O
second    O
messenger    O
synthesised    O
in    O
response    O
to    O
extracellular    O
stimuli    O
.    O

Two    O
formylation    O
reactions    O
are    O
required    O
in    O
the    O
eleven    O
step    O
de    O
novo    O
synthesis    O
of    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(IMP)    I-Nucleotide114964590
,    O
the    O
precursor    O
of    O
the    O
purine    O
ribonucleotides    O
AMP    O
and    O
GMP    O
.    O

Inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
or    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
IMP    B-Nucleotide114964590
)    O
is    O
a    O
nucleoside    O
monophosphate    O
.    O

The    O
umami    O
taste    O
is    O
most    O
frequently    O
associated    O
with    O
the    O
food    O
additive    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
and    O
can    O
be    O
enhanced    O
through    O
the    O
binding    O
of    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
IMP    O
)    O
and    O
guanosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
GMP    O
)    O
molecules    O
.    O

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
(    O
E626    O
)    O
and    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
(    O
E630    O
)    O
.    O

Disodium    B-Nucleotide114964590
inosinate    I-Nucleotide114964590
(    O
E631    B-Nucleotide114964590
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
inosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
IMP    B-Nucleotide114964590
.    O

Bridged    B-Nucleotide114964590
nucleic    I-Nucleotide114964590
acids    I-Nucleotide114964590

A    O
haplogroup    O
is    O
a    O
group    O
of    O
similar    O
haplotypes    O
that    O
share    O
a    O
common    O
ancestor    O
with    O
a    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
mutation    O
.    O

For    O
example    O
,    O
consider    O
a    O
diploid    O
organism    O
and    O
two    O
bi    O
-    O
allelic    O
loci    O
(    O
such    O
as    O
SNPs    B-Nucleotide114964590
)    O
on    O
the    O
same    O
chromosome    O
.    O

The    O
results    O
that    O
comprise    O
the    O
full    O
Y    O
-    O
DNA    O
haplotype    O
from    O
the    O
Y    O
chromosome    O
DNA    O
test    O
can    O
be    O
divided    O
into    O
two    O
parts    O
:    O
the    O
results    O
for    O
UEPs    O
,    O
sometimes    O
loosely    O
called    O
the    O
SNP    O
results    O
as    O
most    O
UEPs    O
are    O
single-nucleotide    B-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
,    O
and    O
the    O
results    O
for    O
microsatellite    O
short    O
tandem    O
repeat    O
sequences    O
(    O
Y    O
-    O
STRs    O
)    O
.    O

The    O
apparent    O
function    O
of    O
HMGA2    O
in    O
proliferation    O
and    O
differentiation    O
of    O
cells    O
during    O
development    O
is    O
supported    O
by    O
the    O
observation    O
that    O
mice    O
with    O
mutant    O
HMGA2    O
genes    O
are    O
unusually    O
small    O
(    O
pygmy    O
phenotype    O
)    O
,    O
and    O
genome    O
-    O
wide    O
association    O
studies    O
linking    O
"    O
HMGA2"-associated    O
SNPs    B-Nucleotide114964590
to    O
variation    O
in    O
human    O
height    O
.    O

Applications    O
for    O
IRIS    O
include    O
microarray    O
format    O
immunoassays    O
,    O
single    O
nucleotide    O
polymorphism    O
(    O
SNP    B-Nucleotide114964590
)    O
detection    O
,    O
pathogen    O
detection    O
and    O
bio    O
-    O
defense    O
monitoring    O
,    O
kinetic    O
analysis    O
of    O
biomolecular    O
interactions    O
,    O
and    O
general    O
biomolecular    O
interaction    O
studies    O
for    O
research    O
applications    O
.    O

The    O
"    O
PHACTR1    O
"    O
gene    O
also    O
contains    O
one    O
of    O
27    O
SNPs    B-Nucleotide114964590
associated    O
with    O
increased    O
risk    O
of    O
coronary    O
artery    O
disease    O
.    O

It    O
analysed    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
in    O
2    O
genes    O
known    O
to    O
vary    O
in    O
power    O
versus    O
endurance    O
athletes    O
,    O
ACTN3    O
and    O
ACE    O
I    O
/    O
D    O
and    O
a    O
gene    O
associated    O
with    O
impact    O
sports    O
head    O
injury    O
,    O
APOE4    O
.    O

Given    O
that    O
synesthesia    O
is    O
known    O
to    O
run    O
in    O
families    O
,    O
it    O
has    O
been    O
suggested    O
that    O
a    O
genetic    O
difference    O
,    O
or    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNPs    O
,    O
pronounced    O
"    O
SNiPs    O
"    O
)    O
might    O
be    O
responsible    O
for    O
either    O
decreased    O
pruning    O
or    O
decreased    O
inhibition    O
in    O
the    O
synesthete    O
brain    O
,    O
leading    O
to    O
increased    O
activation    O
.    O

The    O
primary    O
data    O
comes    O
from    O
sequences    O
of    O
mitochondrial    O
,    O
Y    O
-    O
chromosome    O
and    O
autosomal    O
DNA    O
(    O
including    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
)    O
,    O
from    O
modern    O
populations    O
and    O
,    O
where    O
available    O
,    O
from    O
ancient    O
DNA    O
.    O

The    O
genetic    O
distance    O
between    O
populations    O
is    O
often    O
measured    O
by    O
Fixation    O
index    O
(    O
Fst    O
)    O
,    O
based    O
on    O
genetic    O
polymorphism    O
data    O
,    O
such    O
as    O
single-nucleotide    B-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(SNPs)    I-Nucleotide114964590
or    O
microsatellites    O
.    O

Because    O
the    O
number    O
of    O
genomic    O
variants    O
(    O
usually    O
SNPs    B-Nucleotide114964590
)    O
is    O
usually    O
larger    O
than    O
the    O
sample    O
size    O
,    O
one    O
can    O
not    O
use    O
OLS    O
multiple    O
regression    O
(    O
"    O
p    O
"    O
>    O
"    O
n    O
"    O
problem    O
)    O
.    O

A    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
mutation    O
)    O
,    O
in    O
the    O
sodium    O
/    O
myo    O
-    O
inositol    O
cotransporter    O
(    O
SLC5A3    O
)    O
gene    O
causes    O
FIS    O
.    O

The    O
three    O
largerst    O
patterns    O
of    O
genome    O
-    O
wide    O
SNP    B-Nucleotide114964590
variation    O
in    O
the    O
Netherlands    O
.    O

A    O
study    O
tagging    O
SNPs    B-Nucleotide114964590
from    O
chronic    O
lymphocytic    O
leukemia    O
found    O
GRAMD1B    O
to    O
be    O
the    O
second    O
strongest    O
risk    O
allele    O
region    O
.    O

mtDNA    O
haplogroups    O
are    O
defined    O
by    O
the    O
presence    O
of    O
a    O
series    O
of    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
markers    O
in    O
the    O
hypervariable    O
regions    O
and    O
the    O
coding    O
region    O
of    O
mitochondrial    O
DNA    O
.    O

These    O
genome    O
scans    O
usually    O
utilize    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(SNP)    I-Nucleotide114964590
markers    O
,    O
though    O
use    O
of    O
microsatellites    O
can    O
work    O
as    O
well    O
(    O
with    O
reduced    O
resolution    O
)    O
.    O

A    O
functional    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
a    O
common    O
normal    O
variant    O
)    O
of    O
the    O
gene    O
for    O
catechol    O
-    O
O    O
-    O
methyltransferase    O
results    O
in    O
a    O
valine    O
to    O
methionine    O
mutation    O
at    O
position    O
158    O
(    O
Val158Met    O
)    O
rs4680    O
.    O

single-nucleotide    B-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    B-Nucleotide114964590
)    O

These    O
mutations    O
are    O
also    O
autosomal    O
recessive    O
with    O
three    O
specific    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
being    O
recognized    O
which    O
result    O
in    O
dyskeratosis    O
congenita    O
.    O

A    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
G    O
to    O
C    O
)    O
in    O
the    O
promoter    O
region    O
of    O
the    O
PEMT    O
has    O
been    O
demonstrated    O
to    O
contribute    O
to    O
development    O
of    O
organ    O
dysfunction    O
in    O
conjunction    O
with    O
a    O
low    O
-    O
choline    O
diet    O
.    O

In    O
2014    O
,    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
analysis    O
found    O
Korean    O
cattle    O
to    O
form    O
a    O
distinct    O
group    O
with    O
the    O
Yanbian    O
breed    O
of    O
China    O
,    O
separate    O
from    O
European    O
taurine    O
breeds    O
and    O
distant    O
from    O
the    O
indicine    O
group    O
.    O

Human    O
CYP    O
epoxygenase    O
genes    O
come    O
in    O
many    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
variants    O
some    O
of    O
which    O
code    O
for    O
epoxygenase    O
products    O
with    O
altered    O
activity    O
.    O

Thirdly    O
,    O
to    O
conduct    O
molecular    O
genetic    O
research    O
to    O
identify    O
specific    O
genes    O
involved    O
in    O
abilities    O
and    O
disabilities    O
,    O
e.g.    O
using    O
genetic    O
association    O
(    O
such    O
as    O
genome    O
-    O
wide    O
association    O
)    O
analyses    O
to    O
identify    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
or    O
Copy    O
Number    O
Variants    O
associated    O
with    O
learning    O
and    O
cognitive    O
(    O
dis-)abilities    O
.    O

Single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
are    O
also    O
a    O
genomic    O
variable    O
that    O
adds    O
to    O
the    O
diversity    O
of    O
pathogen    O
strains    O
.    O

Summary    O
statistics    O
of    O
genetic    O
information    O
from    O
the    O
2002    O
-    O
2004    O
followup    O
(    O
mostly    O
Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
)    O
.    O

The    O
objective    O
of    O
this    O
analysis    O
is    O
therefore    O
reduced    O
to    O
differentiating    O
between    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
cytosines    O
and    O
thymidine    O
)    O
resulting    O
from    O
bisulfite    O
conversion    O
(    O
Figure    O
1    O
)    O
.    O

A    O
further    O
improvement    O
to    O
this    O
technique    O
was    O
recently    O
described    O
by    O
Wong    O
et    O
al    O
.    O
,    O
which    O
uses    O
allele    O
-    O
specific    O
primers    O
that    O
incorporate    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
into    O
the    O
sequence    O
of    O
the    O
sequencing    O
primer    O
,    O
thus    O
allowing    O
for    O
separate    O
analysis    O
of    O
maternal    O
and    O
paternal    O
alleles    O
.    O

This    O
method    O
is    O
based    O
on    O
the    O
single    O
-    O
strand    O
conformation    O
polymorphism    O
analysis    O
(    O
SSCA    O
)    O
method    O
developed    O
for    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
analysis    O
.    O

MS    O
-    O
SnuPE    O
employs    O
the    O
primer    O
extension    O
method    O
initially    O
designed    O
for    O
analyzing    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
.    O

In    O
her    O
research    O
,    O
she    O
classified    O
autistic    O
children    O
into    O
subgroups    O
based    O
on    O
their    O
Autism    O
Diagnostic    O
Interview    O
-    O
Revised    O
scores    O
,    O
and    O
,    O
as    O
a    O
result    O
,    O
found    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
which    O
,    O
she    O
says    O
,    O
could    O
allow    O
autism    O
to    O
be    O
diagnosed    O
with    O
over    O
98%    O
accuracy    O
.    O

Impact    O
of    O
single    O
nucleotide    B-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
on    O
aging    O
brain    O
and    O
cognition    O

Defective    O
miR-155    O
function    O
could    O
be    O
implicated    O
in    O
hypertension    O
and    O
cardiovascular    O
diseases    O
if    O
the    O
cis    O
-    O
regulatory    O
site    O
on    O
3    O
`    O
UTR    O
of    O
AT1R    O
(    O
miR-155    O
target    O
site    O
)    O
was    O
affected    O
due    O
to    O
a    O
SNP    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
in    O
AT1R    O
itself    O
.    O

Only    O
one    O
Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
within    O
mir-126    O
has    O
been    O
identified    O
.    O

A    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
in    O
the    O
3    O
'    O
untranslated    O
region    O
(    O
UTR    O
)    O
of    O
HDAC6    O
was    O
found    O
to    O
segregate    O
with    O
the    O
chondrodysplasia    O
.    O

The    O
"    O
CYP17A1    O
"    O
gene    O
also    O
contains    O
one    O
of    O
27    O
SNPs    B-Nucleotide114964590
associated    O
with    O
increased    O
risk    O
of    O
coronary    O
artery    O
disease    O
.    O

Its    O
defining    O
SNP    B-Nucleotide114964590
mutations    O
are    O
L298    O
and    O
P326    O
.    O

In    O
human    O
genetics    O
,    O
Y    O
Haplogroup    O
E    O
-    O
M123    O
is    O
a    O
Y    O
-    O
chromosome    O
haplogroup    O
,    O
and    O
defined    O
by    O
the    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
mutation    O
M123    O
.    O

Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O

Some    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
may    O
confer    O
only    O
a    O
small    O
risk    O
,    O
or    O
may    O
only    O
confer    O
risk    O
in    O
the    O
presence    O
of    O
other    O
mutations    O
or    O
under    O
certain    O
circumstances    O
.    O

Obesity    O
-    O
associated    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
are    O
related    O
to    O
the    O
expression    O
of    O
IRX3    O
(    O
not    O
FTO    O
)    O
in    O
the    O
human    O
brain    O
.    O

It    O
is    O
a    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
in    O
the    O
"    O
SLC6A2    O
"    O
gene    O
in    O
exon    O
9    O
.    O

It    O
is    O
a    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
in    O
the    O
"    O
TPH1    O
"    O
gene    O
and    O
located    O
in    O
intron    O
7    O
.    O

It    O
is    O
a    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
in    O
the    O
"    O
COMT    O
"    O
gene    O
that    O
codes    O
catechol-"O    O
"-    O
Methyltransferase    O
.    O

In    O
domesticated    O
livestock    O
,    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
in    O
imprinted    O
genes    O
influencing    O
foetal    O
growth    O
and    O
development    O
have    O
been    O
shown    O
to    O
be    O
associated    O
with    O
economically    O
important    O
production    O
traits    O
in    O
cattle    O
,    O
sheep    O
and    O
pigs    O
.    O

As    O
of    O
now    O
there    O
are    O
no    O
known    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
that    O
prove    O
to    O
be    O
clinically    O
significant    O
.    O

The    O
program    O
first    O
discards    O
mutations    O
that    O
are    O
known    O
,    O
harmless    O
polymorphisms    B-Nucleotide114964590
by    O
comparison    O
with    O
the    O
integrated    O
databases    O
.    O

The    O
remaining    O
SNPs    O
(    O
Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
)    O
are    O
tested    O
according    O
to    O
the    O
gene    O
alteration    O
they    O
are    O
causing    O
:    O

Single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
are    O
considered    O
to    O
be    O
the    O
largest    O
contributor    O
to    O
genetic    O
variation    O
in    O
humans    O
since    O
they    O
are    O
so    O
abundant    O
and    O
easily    O
detectable    O
.    O

The    O
development    O
of    O
in    O
-    O
depth    O
studies    O
of    O
DNA    O
sequences    O
known    O
as    O
STRs    O
and    O
SNPs    B-Nucleotide114964590
,    O
have    O
allowed    O
geneticists    O
to    O
associate    O
subclades    O
with    O
specific    O
Gaelic    O
kindred    O
groupings    O
(    O
and    O
their    O
surnames    O
)    O
,    O
vindicating    O
significant    O
elements    O
of    O
Gaelic    O
genealogy    O
,    O
as    O
found    O
in    O
works    O
such    O
as    O
the    O
"    O
Leabhar    O
na    O
nGenealach    O
"    O
.    O

The    O
types    O
of    O
molecular    O
markers    O
used    O
to    O
monitor    O
populations    O
are    O
most    O
commonly    O
mitochondrial    O
,    O
microsatellites    O
or    O
single-nucleotide    B-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
,    O
while    O
earlier    O
studies    O
also    O
used    O
allozyme    O
data    O
.    O

The    O
abundance    O
of    O
cryptic    O
or    O
elusive    O
species    O
that    O
are    O
difficult    O
to    O
monitor    O
can    O
be    O
estimated    O
by    O
collecting    O
non    O
-    O
invasive    O
biological    O
samples    O
in    O
the    O
field    O
(    O
e.g.    O
feathers    O
,    O
scat    O
or    O
fur    O
)    O
and    O
using    O
these    O
to    O
identify    O
individuals    O
through    O
microsatellite    O
or    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
genotyping    O
.    O

Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
,    O
a    O
DNA    O
sequence    O
variation    O

More    O
recent    O
work    O
has    O
confirmed    O
that    O
a    O
small    O
proportion    O
of    O
individuals    O
do    O
not    O
produce    O
asparagus    O
urine    O
,    O
and    O
amongst    O
those    O
that    O
do    O
,    O
some    O
can    O
not    O
detect    O
the    O
odour    O
due    O
to    O
a    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
within    O
a    O
cluster    O
of    O
olfactory    O
receptors    O
.    O

Two    O
other    O
typically    O
South    O
Asian    O
lineages    O
,    O
haplogroup    O
H1    O
and    O
haplogroup    O
L3    O
(    O
defined    O
by    O
SNP    B-Nucleotide114964590
mutation    O
M20    O
)    O
have    O
also    O
been    O
observed    O
from    O
few    O
samples    O
.    O

Also    O
,    O
Supple    O
had    O
found    O
evidence    O
of    O
two    O
co    O
-    O
mimics    O
"    O
H.    O
erato    O
"    O
and    O
"    O
H.    O
melpomene    O
"    O
having    O
no    O
shared    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNPs    O
)    O
,    O
which    O
would    O
be    O
indicative    O
of    O
introgression    O
,    O
and    O
hypothesized    O
the    O
same    O
regulatory    O
genes    O
for    O
color    O
/    O
pattern    O
had    O
comparably    O
changed    O
in    O
response    O
to    O
the    O
same    O
selective    O
forces    O
.    O

The    O
Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
variant    O
rs17197    O
in    O
the    O
3    O
'    O
untranslated    O
region    O
of    O
PTGER2    O
has    O
been    O
associated    O
with    O
an    O
increased    O
incidence    O
of    O
essential    O
hypertension    O
in    O
a    O
population    O
of    O
Japanese    O
men    O
.    O

The    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
in    O
the    O
PTGER3    O
,    O
rs977214    O
A    O
/    O
G    O
variant    O
has    O
been    O
associated    O
with    O
an    O
increase    O
in    O
pre    O
-    O
term    O
births    O
in    O
two    O
populations    O
of    O
European    O
ancestry    O
;    O
the    O
SNP    O
variant    O
-1709    O
T    O
>    O

The    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
A    O
/    O
G    O
variant    O
,    O
rs12731181    O
,    O
located    O
in    O
the    O
Three    O
prime    O
untranslated    O
region    O
of    O
PTGFR    O
has    O
been    O
associated    O
with    O
increased    O
risk    O
for    O
hypertension    O
in    O
individuals    O
from    O
southern    O
Germany    O
;    O
while    O
this    O
association    O
was    O
not    O
replicated    O
in    O
other    O
European    O
populations    O
,    O
it    O
was    O
found    O
in    O
a    O
Korean    O
population    O
.    O

An    O
adenine    O
(    O
A    O
)    O
to    O
cytosine    O
(    O
C    O
)    O
synonymous    O
substitution    O
at    O
base    O
984    O
(    O
i.e.    O
A984C    O
)    O
in    O
exon    O
3    O
of    O
"    O
PTGIR    O
"    O
'    O
is    O
the    O
most    O
frequent    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
variant    O
in    O
a    O
sampling    O
of    O
Japanese    O
.    O

Patients    O
with    O
idiopathic    O
achalasia    O
show    O
a    O
significant    O
difference    O
in    O
the    O
distribution    O
of    O
SNP    B-Nucleotide114964590
affecting    O
VIPR1    O
.    O

Almost    O
all    O
haplogroup    O
G1    O
persons    O
have    O
the    O
value    O
of    O
12    O
at    O
short    O
tandem    O
repeat    O
(    O
STR    O
)    O
marker    O
DYS392    O
and    O
all    O
will    O
have    O
the    O
M285    O
or    O
M342    O
SNP    B-Nucleotide114964590
mutation    O
which    O
characterizes    O
this    O
group    O
.    O

The    O
discovery    O
of    O
new    O
SNPs    B-Nucleotide114964590
can    O
result    O
in    O
assignment    O
of    O
new    O
names    O
to    O
haplogroup    O
categories    O
.    O

A    O
number    O
of    O
SNPs    B-Nucleotide114964590
have    O
been    O
identified    O
with    O
seemingly    O
the    O
same    O
coverage    O
in    O
the    O
population    O
as    O
M201    O
.    O

In    O
the    O
field    O
of    O
genetic    O
sequencing    O
,    O
genotyping    O
by    O
sequencing    O
,    O
also    O
called    O
GBS    O
,    O
is    O
a    O
method    O
to    O
discover    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNP    O
)    O
in    O
order    O
to    O
perform    O
genotyping    O
studies    O
,    O
such    O
as    O
genome    O
-    O
wide    O
association    O
studies    O
(    O
GWAS    O
)    O
.    O

Genome    O
-    O
wide    O
complex    O
trait    O
analysis    O
(    O
GCTA    O
)    O
GREML    O
is    O
a    O
statistical    O
method    O
for    O
variance    O
component    O
estimation    O
in    O
genetics    O
which    O
quantifies    O
the    O
total    O
narrowsense    O
(    O
additive    O
)    O
contribution    O
to    O
a    O
trait    O
's    O
heritability    O
of    O
a    O
particular    O
subset    O
of    O
genetic    O
variants    O
(    O
typically    O
limited    O
to    O
SNPs    B-Nucleotide114964590
with    O
MAF    O
>    O
1%    O
,    O
hence    O
terms    O
such    O
as    O
"    O
chip    O
heritability"/"SNP    O
heritability    O
"    O
)    O
.    O

A    O
study    O
of    O
three    O
completely    O
genotyped    O
individuals    O
,    O
white    O
American    O
scientists    O
James    O
Watson    O
and    O
Craig    O
Venter    O
,    O
and    O
Korean    O
scientist    O
Seong    O
-    O
Jin    O
Kim    O
found    O
that    O
the    O
two    O
white    O
scientists    O
have    O
fewer    O
genetic    O
variations    O
(    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
or    O
SNPs    O
)    O
in    O
common    O
than    O
either    O
shares    O
with    O
Kim    O
.    O

The    O
basis    O
for    O
these    O
computations    O
are    O
data    O
describing    O
a    O
large    O
number    O
of    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
,    O
genetic    O
insertions    O
and    O
deletions    O
(    O
indels    O
)    O
,    O
microsatellite    O
markers    O
(    O
or    O
short    O
tandem    O
repeats    O
,    O
STRs    O
)    O
as    O
they    O
appear    O
in    O
each    O
sampled    O
individual    O
.    O

(    O
A.    O
W.    O
F.    O
Edwards    O
,    O
2003    O
but    O
see    O
also    O
infobox    O
"    O
Multi    O
Locus    O
Allele    O
Clusters    O
"    O
)    O
In    O
a    O
test    O
of    O
idealised    O
populations    O
,    O
the    O
computer    O
programme    O
STRUCTURE    O
was    O
found    O
to    O
consistently    O
underestimate    O
the    O
numbers    O
of    O
populations    O
in    O
the    O
data    O
set    O
when    O
high    O
migration    O
rates    O
between    O
populations    O
and    O
slow    O
mutation    O
rates    O
(    O
such    O
as    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
)    O
were    O
considered    O
.    O

A    O
naltrexone    O
treatment    O
study    O
by    O
Anton    O
et    O
al    O
.    O
,    O
released    O
by    O
the    O
National    O
Institutes    O
of    O
Health    O
in    O
February    O
2008    O
and    O
published    O
in    O
the    O
"    O
Archives    O
of    O
General    O
Psychiatry    O
,    O
"    O
has    O
shown    O
that    O
alcoholics    O
having    O
a    O
certain    O
variant    O
of    O
the    O
opioid    O
receptor    O
gene    O
(    O
G    O
polymorphism    O
of    O
SNP    B-Nucleotide114964590
Rs1799971    O
in    O
the    O
gene    O
OPRM1    O
)    O
,    O
known    O
as    O
Asp40    O
,    O
demonstrated    O
strong    O
response    O
to    O
naltrexone    O
and    O
were    O
far    O
more    O
likely    O
to    O
experience    O
success    O
at    O
cutting    O
back    O
or    O
discontinuing    O
their    O
alcohol    O
intake    O
altogether    O
,    O
while    O
for    O
those    O
lacking    O
the    O
gene    O
variant    O
,    O
naltrexone    O
appeared    O
to    O
be    O
no    O
different    O
from    O
placebo    O
.    O

In    O
TPP    O
,    O
the    O
mutations    O
described    O
are    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
located    O
in    O
the    O
hormone    O
response    O
element    O
responsive    O
to    O
thyroid    O
hormone    O
,    O
implying    O
that    O
transcription    O
of    O
the    O
gene    O
and    O
production    O
of    O
ion    O
channels    O
may    O
be    O
altered    O
by    O
increased    O
thyroid    O
hormone    O
levels    O
.    O

It    O
has    O
been    O
suggested    O
that    O
a    O
rare    O
SNP    B-Nucleotide114964590
(    O
rs11614913    O
)    O
that    O
overlaps    O
has    O
-    O
mir-196a2    O
has    O
been    O
found    O
to    O
be    O
associated    O
with    O
non    O
-    O
small    O
cell    O
lung    O
carcinoma    O
.    O

The    O
clinical    O
relevance    O
of    O
this    O
gene    O
includes    O
an    O
intronic    O
SNP    B-Nucleotide114964590
(    O
rs1012068    O
)    O
that    O
has    O
been    O
associated    O
with    O
a    O
2-fold    O
hepatocellular    O
carcinoma    O
-    O
risk    O
increase    O
.    O

Using    O
this    O
folder    O
tab    O
,    O
you    O
are    O
able    O
to    O
do    O
evolution    O
analysis    O
of    O
coding    O
SNPs    B-Nucleotide114964590

It    O
concerns    O
a    O
wide    O
range    O
of    O
scientific    O
and    O
technological    O
approaches    O
:    O
from    O
an    O
in    O
vitro    O
diagnostics    O
to    O
the    O
in    O
vitro    O
fertilisation    O
,    O
from    O
the    O
molecular    O
mechanisms    O
of    O
a    O
cystic    O
fibrosis    O
to    O
the    O
population    O
dynamics    O
of    O
the    O
HIV    O
virus    O
,    O
from    O
the    O
understanding    O
molecular    O
interactions    O
to    O
the    O
study    O
of    O
the    O
carcinogenesis    O
,    O
from    O
a    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
to    O
the    O
gene    O
therapy    O
.    O

SNV    O
calling    O
from    O
NGS    O
data    O
refers    O
to    O
a    O
range    O
of    O
methods    O
for    O
identifying    O
the    O
existence    O
of    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
variant    I-Nucleotide114964590
(    O
SNVs    O
)    O
from    O
the    O
results    O
of    O
next    O
generation    O
sequencing    O
(    O
NGS    O
)    O
experiments    O
.    O

Very    O
often    O
,    O
the    O
searched    O
for    O
variants    O
occur    O
with    O
some    O
(    O
possibly    O
rare    O
)    O
frequency    O
,    O
throughout    O
the    O
population    O
,    O
in    O
which    O
case    O
they    O
may    O
be    O
referred    O
to    O
as    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
.    O

Efficacy    O
of    O
azithromycin    O
against    O
"    O
Mycoplasma    O
genitalium    O
"    O
has    O
decreased    O
substantially    O
,    O
which    O
is    O
thought    O
to    O
occur    O
through    O
SNP    B-Nucleotide114964590
in    O
the    O
23S    O
rRNA    O
gene    O
.    O

However    O
,    O
resistance    O
against    O
moxifloxacin    O
has    O
been    O
observed    O
since    O
2007    O
,    O
thought    O
to    O
be    O
due    O
to    O
"    O
parC    O
"    O
SNP    B-Nucleotide114964590
.    O

S1    O
end    O
mapping    O
-    O
S1    O
nuclease    O
-    O
screening    O
-    O
SDS    O
-    O
PAGE    O
-    O
secondary    O
structure    O
-    O
selection    O
-    O
sense    O
strand    O
-    O
sequence    O
-    O
sequence    O
motif    O
-    O
sequence    O
polymorphism    O
-    O
sequence    O
-    O
tagged    O
site    O
-    O
sequential    O
epitope    O
-    O
severe    O
combined    O
immunodeficiency    O
-    O
sex    O
chromosome    O
-    O
sex    O
-    O
linked    O
-    O
Shine    O
-    O
Dalgarno    O
sequence    O
-    O
shotgun    O
cloning    O
-    O
shotgun    O
cloning    O
or    O
sequencing    O
-    O
shotgun    O
sequencing    O
-    O
shuttle    O
vector    O
-    O
sickle    O
-    O
cell    O
disease    O
-    O
side    O
chain    O
-    O
sigma    O
factor    O
-    O
signal    O
peptidase    O
-    O
signal    O
sequence    O
-    O
silent    O
mutation    O
-    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
-    O
siRNA    O
-    O
site    O
-    O
directed    O
mutagenesis    O
-    O
site    O
-    O
specific    O
recombination    O
-    O
slot    O
blot    O
-    O
SNP    B-Nucleotide114964590
-    O
snRNA    O
-    O
snRNP    O
-    O
solution    O
hybridization    O
-    O
somatic    O
cells    O
-    O
Southern    O
blot    O
-    O
southwestern    O
blot    O
-    O
SP6    O
RNA    O
polymerase    O
-    O
spectral    O
karyotype    O
-    O
splicing    O
-    O
Simple    O
Sequence    O
Repeats    O
(    O
SSR    O
)    O
-    O
stable    O
transfection    O
-    O
start    O
codon    O
-    O
stem    O
-    O
loop    O
-    O
sticky    O
end    O
-    O
stop    O
codon    O
-    O
streptavidin    O
-    O
stringency    O
-    O
structural    O
motif    O
-    O
sub    O
-    O
cloning    O
-    O
substitution    O
-    O
suicide    O
gene    O
-    O
supercoil    O
-    O
syndrome    O
-    O

Missense    O
single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590
in    O
the    O
SIAE    O
gene    O
has    O
also    O
been    O
associated    O
with    O
the    O
anti    O
-    O
PIT-1    O
antibody    O
syndrome    O
,    O
a    O
novel    O
clinical    O
entity    O
related    O
to    O
autoimmune    O
polyglandular    O
syndrome    O
(    O
APS    O
)    O
.    O

Rhabdoid    O
tumors    O
have    O
a    O
distinctive    O
histology    O
and    O
abnormalities    O
(    O
i.e.    O
loss    O
of    O
heterozygosity    O
,    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
,    O
and    O
deletions    O
)    O
in    O
chromosome    O
22    O
.    O

In    O
2008    O
,    O
multiplex    O
-    O
PCR    O
was    O
used    O
for    O
analysis    O
of    O
microsatellites    O
and    O
SNPs    B-Nucleotide114964590
.    O

It    O
is    O
not    O
surprising    O
therefore    O
that    O
mutations    O
or    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
in    O
factor    O
H    O
often    O
result    O
in    O
pathologies    O
.    O

The    O
goal    O
of    O
the    O
Cancer    O
Genome    O
Anatomy    O
Project    O
Genome    O
Annotation    O
Initiative    O
(    O
CGAP    O
-    O
GAI    O
)    O
is    O
to    O
discover    O
and    O
catalogue    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphisms    I-Nucleotide114964590
(    O
SNPs    O
)    O
that    O
correlate    O
with    O
cancer    O
initiation    O
and    O
progression    O
.    O

A    O
JDP2    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
was    O
detected    O
in    O
Japanese    O
,    O
Korean    O
,    O
and    O
Dutch    O
cohorts    O
,    O
and    O
is    O
associated    O
with    O
an    O
increased    O
risk    O
of    O
intracranial    O
aneurysms    O
.    O

Genomic    O
biomarkers    O
analyze    O
DNA    O
by    O
identifying    O
irregular    O
sequences    O
in    O
the    O
genome    O
,    O
typically    O
a    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
.    O

This    O
is    O
also    O
known    O
as    O
"    O
marker    O
-    O
assisted    O
"    O
congenics    O
,    O
due    O
to    O
the    O
use    O
of    O
genetic    O
markers    O
,    O
typically    O
microsatellite    O
markers    O
,    O
but    O
now    O
,    O
more    O
commonly    O
,    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
markers    O
(    O
SNPs    O
)    O
.    O

Single-nucleotide    B-Nucleotide114964590
polymorphism    I-Nucleotide114964590

Genetic    O
association    O
can    O
be    O
between    O
phenotypes    O
,    O
such    O
as    O
visible    O
characteristics    O
such    O
as    O
flower    O
colour    O
or    O
height    O
,    O
between    O
a    O
phenotype    O
and    O
a    O
genetic    O
polymorphism    O
,    O
such    O
as    O
a    O
single    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
polymorphism    I-Nucleotide114964590
(    O
SNP    O
)    O
,    O
or    O
between    O
two    O
genetic    O
polymorphisms    O
.    O

diquafosol    B-Nucleotide114964590
(    O
INN    O
)    O

GAR    O
+    O
fTHF    O
→    O
fGAR    B-Nucleotide114964590
+    O
THF    O

Deoxyguanosine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590

Xanthosine    B-Nucleotide114964590
5'-triphosphate    I-Nucleotide114964590
(    O
XTP    B-Nucleotide114964590
)    O
is    O
a    O
nucleotide    O
that    O
is    O
not    O
produced    O
by    O
-    O
and    O
has    O
no    O
known    O
function    O
in    O
-    O
living    O
cells    O
.    O

M    O
-    O
Ras    O
shares    O
a    O
similar    O
structure    O
with    O
H    O
-    O
Ras    O
and    O
Rap2A    O
with    O
the    O
exception    O
of    O
its    O
switch    O
1    O
conformation    O
when    O
bound    O
to    O
guanosine    O
5'-(beta    O
,    O
gamma    O
-    O
imido)triphosphate    O
(    O
Gpp(NH)p    B-Nucleotide114964590
)    O
.    O

C    O
-    O
terminus    O
-    O
C4    O
photosynthesis    O
-    O
cadherin    O
-    O
calbindin    O
-calcitonin    O
-    O
calcitonin    O
gene    O
-    O
related    O
peptide    O
-    O
calcitonin    O
gene    O
-    O
related    O
peptide    O
receptor    O
-    O
calcitonin    O
receptor    O
-    O
calcitriol    O
receptor    O
-    O
calcium    O
channel    O
-    O
calcium    O
signaling    O
-    O
calcium    O
-    O
binding    O
protein    O
-    O
Calmodulin    O
-    O
calmodulin    O
-    O
binding    O
protein    O
-    O
Calvin    O
cycle    O
-    O
CAM    O
photosynthesis    O
-    O
CAM    O
plants    O
-    O
cancer    O
-    O
capsid    O
-    O
Carbohydrate    O
-    O
Carbon    O
-    O
Carbon    O
fixation    O
-    O
Carboxylic    O
acid    O
-    O
carcinoembryonic    O
antigen    O
-    O
carrier    O
-    O
carrier    O
protein    O
-    O
CAS    O
registry    O
number    O
-    O
casein    O
-    O
catabolism    O
-    O
catalyst    O
-    O
catalytic    O
domain    O
-    O
CCR5    O
receptor    O
-    O
CD4    O
antigen    O
-    O
CD45    O
antigen    O
-    O
CD95    O
antigen    O
-    O
CDC28    O
protein    O
kinase    O
-    O
cell    O
-    O
cell    O
adhesion    O
molecule    O
-    O
Cell    O
biology    O
-    O
cell    O
cycle    O
protein    O
-    O
cell    O
membrane    O
-    O
cell    O
membrane    O
transport    O
-    O
cell    O
nucleus    O
-    O
cell    O
surface    O
receptor    O
-    O
cellular    O
respiration    O
-    O
cellulose    O
-    O
centriole    O
-    O
centromere    O
-    O
centrosome    O
-    O
Chaperone    O
-    O
Chelation    O
-    O
Chemical    O
bond    O
-    O
Chemical    O
compound    O
-    O
Conformation    O
-    O
chemical    O
element    O
-    O
Chemical    O
equilibrium    O
-    O
Chemical    O
formula    O
-    O
Chemical    O
nomenclature    O
-    O
Chemical    O
property    O
-    O
Chemical    O
reaction    O
-    O
Chemical    O
series    O
-    O
Chemical    O
thermodynamics    O
-    O
Cheminformatics    O
-    O
chemiosmosis    O
-    O
chemiosmotic    O
hypothesis    O
-    O
chemiosmotic    O
potential    O
-    O
Chemist    O
-    O
Chemistry    O
-    O
Chemistry    O
basic    O
topics    O
-    O
chemotroph    O
-    O
chemokine    O
receptor    O
-    O
chemoreceptor    O
-    O
chiasma    O
-    O
Chimera    O
(    O
protein    O
)    O
-    O
chimeric    O
protein    O
-    O
Chirality    O
-    O
chloride    O
channel    O
-    O
chlorophyll    O
-    O
chloroplast    O
-    O
chloroplast    O
membrane    O
-    O
cholecystokinin    O
receptor    O
-    O
cholesterine    O
-    O
cholinergic    O
receptor    O
-    O
chorionic    O
gonadotropin    O
-    O
chromatid    O
-    O
chromatin    O
-    O
ciclosporin    O
-    O
Chromatography    O
-    O
Chromosomal    O
crossover    O
-    O
chromosome    O
-    O
chromosome    O
walking    O
-    O
cilium    O
-    O
circular    O
dichroism    O
-    O
-    O
cis    O
face    O
-    O
Citric    O
acid    O
-    O
Citric    O
acid    O
cycle    O
-    O
cladistics    O
-    O
cloning    O
-    O
coenzyme    O
-    O
cofactor    O
(    O
biochemistry    O
)    O
-    O
colchicine    O
-    O
collagen    O
-    O
colloid    O
-    O
colony    O
-    O
stimulating    O
factor    O
-    O
Colony    O
stimulating    O
factor    O
1    O
receptor    O
-    O
Colorimeter    O
-    O
comparative    O
biochemistry    O
-    O
competitive    O
inhibition    O
-    O
complement    O
3A    O
-    O
complement    O
5A    O
-    O
complement    O
factor    O
B    O
-    O
complement    O
membrane    O
attack    O
complex    O
-    O
complement    O
receptor    O
-    O
complex    O
-    O
computational    O
biology    O
-    O
computational    O
chemistry    O
-    O
computational    O
genomics    O
-    O
concanavalin    O
A    O
-    O
Concentration    O
-    O
concentration    O
gradient    O
-    O
consensus    O
sequence    O
-    O
conserved    O
sequence    O
-    O
Cooperative    O
-    O
Cooperative    O
binding    O
-    O
Cooperativity    O
-    O
cooperativity    O
cellular    O
respiration    O
-    O
corticotropin    O
-    O
corticotropin    O
receptor    O
-    O
corticotropin    O
-    O
releasing    O
hormone    O
-    O
corticotropin    O
-    O
releasing    O
hormone    O
receptor    O
-    O
cotransport    O
metabolism    O
-    O
covalent    O
bond    O
-    O
Covalent    O
radius    O
-    O
CpG    O
island    O
-    O
cristae    O
-    O
cryptobiology    O
-    O
Crystal    O
structure    O
-    O
Crystallography    O
-    O
cuticula    O
-    O
CXCR4    O
receptor    O
-    O
cyclic    O
AMP    O
receptor    O
-    O
cyclic    O
AMP    O
receptor    O
protein    O
-    O
cyclic    O
AMP    O
-    O
responsive    O
DNA    O
-    O
binding    O
protein    O
-    O
cyclic    O
electron    O
flow    O
-    O
Cyclic    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
-    O
cyclic    O
peptide    O
-    O
cyclin    O
-    O
cyclin    O
A    O
-    O
cyclin    O
B    O
-    O
cyclin    O
E    O
-    O
cyclin    O
-    O
dependent    O
kinase    O
-    O
cycloleucine    O
-    O
cyclosporin    O
-    O
cyclosporine    O
-    O
cystatin    O
-    O
cysteine    O
-    O
cystic    O
fibrosis    O
transmembrane    O
conductance    O
regulator    O
-    O
cytochrome    O
B    O
-    O
cytochrome    O
C    O
-    O
cytochrome    O
P-450    O
-    O
cytochrome    O
P-450    O
CYP1A1    O
-    O
cytochrome    O
C    O
oxidase    O
-    O
cytokine    O
receptor    O
-    O
cytoplasm    O
-    O
cytoplasmic    O
and    O
nuclear    O
receptor    O
-    O
Cytosine    O
-    O
cytoskeletal    O
protein    O
-    O
cytoskeleton    O
-    O
cytosol    O
-    O
cytotoxic    O
T    O
cell    O
-    O

Cyclic    B-Nucleotide114964590
dinucleotides    I-Nucleotide114964590
-    O
second    O
-    O
messenger    O
signaling    O
molecules    O
produced    O
by    O
diverse    O
bacterial    O
species    O
were    O
detected    O
in    O
the    O
cytosol    O
of    O
mammalian    O
cells    O
during    O
intracellular    O
pathogen    O
infection    O
;    O
this    O
leads    O
to    O
activation    O
of    O
TBK1-IRF3    O
and    O
the    O
downstream    O
production    O
of    O
type    O
I    O
interferon    O
.    O

This    O
G    O
protein    O
subunit    O
activates    O
a    O
taste    O
phosphodiesterase    O
and    O
decreases    O
cyclic    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
levels    O
.    O

8-Bromoguanosine    B-Nucleotide114964590
3',5'-cyclic    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
8-Br    O
-    O
cGMP    O
)    O

denufosol    B-Nucleotide114964590
tetrasodium    I-Nucleotide114964590
(    O
USAN    O
)    O

Disodium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
,    O
also    O
known    O
as    O
sodium    B-Nucleotide114964590
5'-guanylate    I-Nucleotide114964590
and    O
disodium    B-Nucleotide114964590
5'-guanylate    I-Nucleotide114964590
,    O
is    O
a    O
natural    O
sodium    O
salt    O
of    O
the    O
flavor    O
enhancing    O
nucleotide    O
guanosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
GMP    O
)    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
(    O
E626    O
)    O
and    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
(    O
E630    O
)    O
.    O

It    O
reversibly    O
inhibits    O
inosine    O
monophosphate    O
dehydrogenase    O
,    O
the    O
enzyme    O
that    O
controls    O
the    O
rate    O
of    O
synthesis    O
of    O
guanine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
in    O
the    O
"    O
de    O
novo    O
"    O
pathway    O
of    O
purine    O
synthesis    O
used    O
in    O
the    O
proliferation    O
of    O
B    O
and    O
T    O
lymphocytes    O
.    O

Guanosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590

:    O
ATP    O
+    O
GMP    B-Nucleotide114964590
ADP    O
+    O
GDP    B-Nucleotide114964590

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP-mannose    B-Nucleotide114964590
and    O
(    O
phosphomannan)n    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GMP    B-Nucleotide114964590
and    O
(    O
phosphomannan)n+1    O
.    O

In    O
humans    O
,    O
orotidine    O
occurs    O
as    O
its    O
5'-phosphate    O
(    O
orotidylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
)    O
,    O
which    O
is    O
an    O
intermediate    O
in    O
pyrimidine    O
nucleotide    O
biosynthesis    O
(    O
cytidine    O
and    O
uridine    O
)    O
that    O
are    O
found    O
in    O
nucleic    O
acids    O
.    O

Interfering    O
with    O
miR-205    O
function    O
by    O
using    O
a    O
synthetic    O
antagomir    B-Nucleotide114964590
,    O
or    O
by    O
the    O
ectopic    O
expression    O
of    O
miR-184    O
,    O
is    O
thought    O
to    O
lead    O
to    O
a    O
coordinated    O
damping    O
of    O
the    O
Akt    O
signaling    O
pathway    O
via    O
SHIP2    O
induction    O
.    O

Adenylosuccinate    O
lyase    O
converts    O
adenylosuccinate    B-Nucleotide114964590
to    O
AMP    O
and    O
fumarate    O
as    O
part    O
of    O
the    O
purine    O
nucleotide    O
cycle    O
.    O

The    O
genome    O
of    O
its    O
mitochondria    O
is    O
also    O
exceptionally    O
small    O
and    O
has    O
a    O
very    O
high    O
GC    B-Nucleotide114964590
skew    I-Nucleotide114964590
,    O
while    O
the    O
genome    O
of    O
its    O
plastids    O
is    O
of    O
normal    O
size    O
but    O
contains    O
an    O
unusual    O
number    O
of    O
stem    O
-    O
loop    O
structures    O
.    O

Chen    O
used    O
the    O
additional    O
funding    O
to    O
expand    O
his    O
research    O
into    O
how    O
NF-κB    O
initiated    O
immune    O
responses    O
to    O
RNA    O
viruses    O
such    O
as    O
influenza    O
and    O
hepatitis    O
C.    O
This    O
new    O
line    O
of    O
research    O
led    O
to    O
several    O
discoveries    O
,    O
such    O
as    O
MAVS    O
,    O
cGAS    O
and    O
cGAMP    B-Nucleotide114964590
,    O
which    O
contribute    O
to    O
understanding    O
innate    O
immune    O
sensing    O
and    O
signaling    O
of    O
cytosolic    O
nucleic    O
acids    O
.    O

Novel    O
,    O
very    O
promising    O
,    O
experimental    O
therapeutic    O
regimens    O
rely    O
on    O
antisense    O
technology    O
:    O
phosphorodiamidate    B-Nucleotide114964590
morpholino    I-Nucleotide114964590
oligomers    I-Nucleotide114964590
(    O
PMOs    O
)    O
targeting    O
the    O
MARV    O
genome    O
could    O
prevent    O
disease    O
in    O
nonhuman    O
primates    O
.    O

In    O
early    O
2006    O
,    O
scientists    O
studying    O
the    O
Ebola    O
hemorrhagic    O
fever    O
virus    O
at    O
USAMRIID    O
announced    O
a    O
75%    O
recovery    O
rate    O
after    O
infecting    O
four    O
rhesus    O
monkeys    O
and    O
then    O
treating    O
them    O
with    O
an    O
antisense    O
Morpholino    B-Nucleotide114964590
drug    O
developed    O
by    O
Sarepta    O
Therapeutics    O
(    O
formerly    O
named    O
AVI    O
BioPharma    O
)    O
,    O
a    O
U.S.    O
biotechnology    O
firm    O
.    O

Morpholino    B-Nucleotide114964590

Gene    O
Tools    O
,    O
LLC    O
is    O
a    O
limited    O
liability    O
company    O
located    O
in    O
Philomath    O
,    O
Oregon    O
,    O
United    O
States    O
that    O
manufactures    O
Morpholino    B-Nucleotide114964590
antisense    O
oligo    B-Nucleotide114964590
and    O
delivery    O
reagents    O
.    O

An    O
example    O
of    O
a    O
phosphorodiamidate    O
is    O
Morpholino    B-Nucleotide114964590
which    O
is    O
used    O
in    O
molecular    O
biology    O
.    O

Two    O
types    O
of    O
neutral    O
ON    O
analogues    O
,    O
peptide    O
nucleic    O
acid    O
(    O
PNA    B-Nucleotide114964590
)    O
and    O
phosphorodiamidate    O
morpholino    O
oligomers    O
(    O
PMO    O
or    O
Morpholino    B-Nucleotide114964590
)    O
are    O
becoming    O
dominant    O
in    O
this    O
area    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dGTP    B-Nucleotide114964590
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
deoxyguanosine    O
and    O
triphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
vitexin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Nucleotide114964590
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
D    O
-    O
glucoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
vomilenine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Nucleotide114964590
and    O
raucaffricine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-galactose    B-Nucleotide114964590
and    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylprotein    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Nucleotide114964590
and    O
4-beta    O
-    O
D    O
-    O
galactosyl    O
-    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylprotein    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
D    O
-    O
xylose    O
and    O
zeatin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Nucleotide114964590
and    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylzeatin    O
.    O

The    O
substrates    O
for    O
RNR    O
are    O
ADP    O
,    O
GDP    B-Nucleotide114964590
,    O
CDP    B-Nucleotide114964590
and    O
UDP    B-Nucleotide114964590
.    O

Matching    O
these    O
structural    O
relationships    O
,    O
GPR17    O
has    O
been    O
reported    O
to    O
be    O
activated    O
by    O
cysteinyl    O
leukotrienes    O
(    O
i.e.    O
LTC4    O
and    O
LTD4    O
)    O
as    O
well    O
as    O
the    O
purines    O
(    O
i.e.    O
,    O
uridine    O
,    O
Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
,    O
UDP-glucose    B-Nucleotide114964590
)    O
.    O

Studies    O
focusing    O
on    O
nerve    O
tissue    O
indicate    O
that    O
GPR17    O
is    O
:    O
a    O
)    O
highly    O
expressed    O
in    O
precursors    O
to    O
mature    O
oligodendrocytes    O
but    O
not    O
expressed    O
in    O
mature    O
oligodendrocytes    O
,    O
suggesting    O
that    O
GPR17    O
must    O
be    O
down    O
-    O
regulated    O
in    O
order    O
for    O
precursor    O
cells    O
to    O
proceed    O
to    O
terminal    O
oligodendrocyte    O
differentiation    O
;    O
b    O
)    O
activated    O
by    O
uridine    O
,    O
Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
and    O
UDP-glucose    B-Nucleotide114964590
to    O
stimulate    O
outward    O
K+    O
channels    O
and    O
the    O
aforementioned    O
maturation    O
responses    O
in    O
oligodenrocyte    O
precursor    O
cells    O
;    O
c    O
)    O
also    O
activated    O
by    O
LTC4    O
and    O
LTD4    O
;    O
d    O
)    O
more    O
highly    O
expressed    O
in    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
tissues    O
of    O
animal    O
models    O
undergoing    O
ischemia    O
,    O
Experimental    O
autoimmune    O
encephalomyelitis    O
,    O
and    O
focal    O
demyelination    O
as    O
well    O
as    O
in    O
the    O
CNS    O
tissues    O
of    O
humans    O
suffering    O
brain    O
damage    O
due    O
to    O
ischemia    O
,    O
trauma    O
,    O
and    O
multiple    O
sclerosis    O
;    O
e    O
)    O
expressed    O
in    O
injured    O
neurons    O
and    O
associated    O
with    O
the    O
rapid    O
death    O
and    O
clearance    O
of    O
these    O
neurons    O
in    O
a    O
model    O
of    O
mouse    O
spinal    O
cord    O
crush    O
injury    O
;    O
f    O
)    O
acts    O
to    O
reduce    O
the    O
extent    O
of    O
spinal    O
cord    O
injury    O
in    O
the    O
latter    O
model    O
based    O
on    O
the    O
increased    O
extent    O
of    O
injury    O
in    O
GPR17-depleted    O
mice    O
;    O
and    O
g    O
)    O
acts    O
to    O
reduce    O
inflammation    O
,    O
elevate    O
hippocampus    O
neurogenesis    O
,    O
and    O
improve    O
learning    O
and    O
memory    O
in    O
a    O
rat    O
model    O
of    O
age    O
-    O
related    O
cognitive    O
impairment    O
based    O
on    O
the    O
effects    O
of    O
the    O
GPR17    O
antagonist    O
,    O
montelukast    O
,    O
as    O
well    O
as    O
of    O
GPR17    O
depletion    O
.    O

This    O
receptor    O
is    O
responsive    O
to    O
UDP    B-Nucleotide114964590
,    O
partially    O
responsive    O
to    O
UTP    B-Nucleotide114964590
and    O
ADP    O
,    O
and    O
not    O
responsive    O
to    O
ATP    O
.    O

Before    O
monosaccharide    O
units    O
are    O
incorporated    O
into    O
glycoproteins    O
,    O
polysaccharides    O
,    O
or    O
lipids    O
in    O
living    O
organisms    O
,    O
they    O
are    O
typically    O
first    O
"    O
activated    O
"    O
by    O
being    O
joined    O
via    O
a    O
glycosidic    O
bond    O
to    O
the    O
phosphate    O
group    O
of    O
a    O
nucleotide    O
such    O
as    O
uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
,    O
guanosine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
GDP    O
)    O
,    O
thymidine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
TDP    O
)    O
,    O
or    O
cytidine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
CMP    O
)    O
.    O

Once    O
the    O
incoming    O
galactose    O
has    O
been    O
converted    O
into    O
galactose    O
1-phosphate    O
(    O
Gal-1-P    O
)    O
,    O
it    O
is    O
involved    O
in    O
a    O
reaction    O
with    O
UDP-glucose    B-Nucleotide114964590
,    O
a    O
glucose    O
molecule    O
bonded    O
to    O
uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
UDP    O
)    O
.    O

They    O
can    O
do    O
this    O
by    O
way    O
of    O
reglucosylating    O
these    O
glycoproteins    O
by    O
an    O
enzyme    O
called    O
UDP    B-Nucleotide114964590
-    O
glucose    O
-    O
glycoprotein    O
glucosyltransferase    O
.    O

The    O
crystal    O
structure    O
of    O
O    O
-    O
GlcNAc    O
transferase    O
has    O
not    O
been    O
well    O
studied    O
,    O
but    O
the    O
structure    O
of    O
a    O
binary    O
complex    O
with    O
UDP    O
and    O
a    O
ternary    O
complex    O
with    O
UDP    B-Nucleotide114964590
and    O
a    O
peptide    O
substrate    O
has    O
been    O
researched    O
.    O

Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
,    O
abbreviated    O
UDP    B-Nucleotide114964590
,    O
is    O
a    O
nucleotide    O
diphosphate    O
.    O

UDP    B-Nucleotide114964590

Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
galactose    I-Nucleotide114964590
(    O
UDP    B-Nucleotide114964590
-    O
galactose    O
)    O
is    O
an    O
intermediate    O
in    O
the    O
production    O
of    O
polysaccharides    O
.    O

Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
UMP    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UDP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
galactosamine    O
and    O
glycoprotein    O
-    O
alpha    O
-    O
L    O
-    O
fucosyl-(1,2)-D    O
-    O
galactose    O
,    O
whereas    O
its    O
3    O
products    O
are    O
UDP    B-Nucleotide114964590
,    O
[    O
[    O
glycoprotein    O
-    O
N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
galactosaminyl-(1,3)-[alpha    O
-    O
L    O
-    O
fucosyl-    O
]    O
]    O
,    O
and    O
[    O
[    O
(    O
1,2)]-D    O
-    O
galactose    O
]    O
]    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP-glucose    B-Nucleotide114964590
.    O

:    O
(    O
1    O
)    O
CDP-choline    B-Nucleotide114964590
+    O
H2O    O
CMP    O
+    O
phosphocholine    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP-choline    B-Nucleotide114964590
and    O
sphingosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Nucleotide114964590
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

Glycineamide    B-Nucleotide114964590
ribonucleotide    I-Nucleotide114964590

DEAD    O
box    O
proteins    O
were    O
first    O
brought    O
to    O
attention    O
in    O
the    O
late    O
1980s    O
in    O
a    O
study    O
that    O
looked    O
at    O
a    O
group    O
of    O
NTP    B-Nucleotide114964590
binding    I-Nucleotide114964590
site    I-Nucleotide114964590
that    O
were    O
similar    O
in    O
sequence    O
to    O
the    O
eIF4A    O
RNA    O
helicase    O
sequence    O
.    O

Calcium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
is    O
a    O
compound    O
with    O
formula    O
Ca(C10H12O4N5PO4    O
)    O
.    O

Cangrelor    B-Nucleotide114964590
(    O
trade    O
name    O
Kengreal    B-Nucleotide114964590
in    O
the    O
US    O
and    O
Kengrexal    B-Nucleotide114964590
in    O
Europe    O
)    O
is    O
a    O
P2Y12    O
inhibitor    O
FDA    O
approved    O
as    O
of    O
June    O
2015    O
as    O
an    O
antiplatelet    O
drug    O
for    O
intravenous    O
application    O
.    O

Adenosine    B-Nucleotide114964590
thiamine    I-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
AThDP    O
)    O
,    O
or    O
thiaminylated    O
adenosine    O
diphosphate    O
(    O
ADP    O
)    O
is    O
a    O
naturally    O
occurring    O
thiamine    O
adenine    O
nucleotide    O
.    O

Vidarabine    B-Nucleotide114964590
phosphate    I-Nucleotide114964590
is    O
an    O
adenosine    O
monophosphate    O
nucleotide    O
in    O
which    O
ribose    O
is    O
replaces    O
by    O
an    O
arabinso    O
moiety    O
.    O

This    O
is    O
quickly    O
followed    O
by    O
accumulation    O
of    O
chromatin    O
remodeler    O
Alc1    O
,    O
which    O
has    O
an    O
ADP-ribose    B-Nucleotide114964590
–    O
binding    O
domain    O
,    O
allowing    O
it    O
to    O
be    O
quickly    O
attracted    O
to    O
the    O
product    O
of    O
PARP1    O
.    O

:    O
(    O
2    O
)    O
ADP-ribose    B-Nucleotide114964590
+    O
H2O    O
AMP    O
+    O
D    O
-    O
ribose    O
5-phosphate    O

In    O
molecular    O
biology    O
,    O
the    O
Macro    O
domain    O
or    O
A1pp    O
domain    O
is    O
a    O
module    O
of    O
about    O
180    O
amino    O
acids    O
which    O
can    O
bind    O
ADP-ribose    B-Nucleotide114964590
,    O
an    O
NAD    O
metabolite    O
,    O
or    O
related    O
ligands    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ADP    O
and    O
D    O
-    O
ribose    O
5-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
ADP-ribose    B-Nucleotide114964590
.    O

Unlike    O
Q    O
-    O
FISH    O
,    O
Flow    O
-    O
FISH    O
utilizes    O
the    O
quantitative    O
properties    O
of    O
telomere    O
specific    O
PNA    B-Nucleotide114964590
probe    O
retention    O
to    O
quantify    O
median    O
fluorescence    O
in    O
a    O
population    O
of    O
cells    O
,    O
via    O
the    O
use    O
of    O
a    O
flow    O
cytometer    O
,    O
instead    O
of    O
a    O
fluorescence    O
microscope    O
.    O

This    O
chapters    O
describes    O
efforts    O
to    O
define    O
life    O
and    O
how    O
it    O
emerged    O
from    O
inanimate    O
matter    O
(    O
Abiogenesis    O
)    O
and    O
even    O
recreate    O
Artificial    O
life    O
including    O
:    O
the    O
Miller    O
–    O
Urey    O
experiment    O
by    O
chemists    O
Stanley    O
Miller    O
and    O
Harold    O
Urey    O
at    O
the    O
University    O
of    O
Chicago    O
in    O
1953    O
to    O
spark    O
life    O
into    O
a    O
mixture    O
of    O
chemicals    O
by    O
using    O
an    O
electrical    O
charge    O
;    O
Steen    O
Rasmussen    O
's    O
work    O
at    O
the    O
Los    O
Alamos    O
National    O
Laboratory    O
to    O
implant    O
primitive    O
DNA    O
,    O
Peptide    B-Nucleotide114964590
nucleic    I-Nucleotide114964590
acid    I-Nucleotide114964590
,    O
into    O
soap    O
molecules    O
and    O
heat    O
them    O
up    O
;    O
and    O
the    O
work    O
of    O
the    O
Institute    O
for    O
Complex    O
Adaptive    O
Matter    O
at    O
the    O
University    O
of    O
California    O
.    O

In    O
biochemistry    O
,    O
the    O
term    O
oligonucleotide    B-Nucleotide114964590
–    O
or    O
,    O
informally    O
,    O
"    O
oligo    O
"    O
-    O
is    O
used    O
for    O
short    O
,    O
single    O
-    O
stranded    O
nucleic    O
acid    O
fragments    O
,    O
such    O
as    O
DNA    O
or    O
RNA    O
,    O
or    O
similar    O
fragments    O
of    O
analogs    O
of    O
nucleic    O
acids    O
such    O
as    O
peptide    B-Nucleotide114964590
nucleic    I-Nucleotide114964590
acid    I-Nucleotide114964590
or    O
Morpholino    B-Nucleotide114964590
.    O

They    O
can    O
be    O
formed    O
of    O
DNA    O
,    O
RNA    O
,    O
LNA    O
,    O
and    O
PNA    B-Nucleotide114964590
,    O
and    O
may    O
be    O
intramolecular    O
,    O
bimolecular    O
,    O
or    O
tetramolecular    O
.    O

Peptide    B-Nucleotide114964590
nucleic    I-Nucleotide114964590
acid    I-Nucleotide114964590

Two    O
types    O
of    O
neutral    O
ON    O
analogues    O
,    O
peptide    O
nucleic    O
acid    O
(    O
PNA    B-Nucleotide114964590
)    O
and    O
phosphorodiamidate    O
morpholino    O
oligomers    O
(    O
PMO    O
or    O
Morpholino    B-Nucleotide114964590
)    O
are    O
becoming    O
dominant    O
in    O
this    O
area    O
.    O

AIR    O
+    O
CO2    O
→    O
CAIR    B-Nucleotide114964590
+    O
2H+    O

If    O
the    O
correct    O
anticodon    O
binds    O
to    O
the    O
mRNA    O
codon    O
,    O
the    O
ribosome    O
changes    O
configuration    O
and    O
alters    O
the    O
geometry    O
of    O
the    O
GTPase    O
domain    O
of    O
EF    O
-    O
Tu    O
,    O
resulting    O
in    O
the    O
hydrolysis    O
of    O
the    O
GTP    O
associated    O
with    O
the    O
EF    O
-    O
Tu    O
to    O
GDP    B-Nucleotide114964590
and    O
Pi    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

In    O
an    O
example    O
of    O
feedback    O
inhibition    O
,    O
ATase    O
is    O
inhibited    O
mainly    O
by    O
the    O
end    O
-    O
products    O
of    O
the    O
purine    O
synthesis    O
pathway    O
,    O
AMP    O
,    O
GMP    B-Nucleotide114964590
,    O
ADP    O
,    O
and    O
GDP    B-Nucleotide114964590
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Nucleotide114964590
for    O
GTP    B-Nucleotide114964590
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Nucleotide114964590
to    O
GDP    B-Nucleotide114964590
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Nucleotide114964590
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Nucleotide114964590
from    O
another    O
phosphorylated    O
compound    O
.    O

EF    O
-    O
Ts    O
serves    O
as    O
the    O
guanine    O
nucleotide    O
exchange    O
factor    O
for    O
EF    O
-    O
Tu    O
(    O
elongation    O
factor    O
thermo    O
unstable    O
)    O
,    O
catalyzing    O
the    O
release    O
of    O
guanosine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
from    O
EF    O
-    O
Tu    O
.    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Nucleotide114964590
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Nucleotide114964590
)    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Nucleotide114964590
for    O
GDP    B-Nucleotide114964590
bound    O
to    O
G-α    O
subunit    O
.    O

:    O
ATP    O
+    O
GMP    B-Nucleotide114964590
ADP    O
+    O
GDP    B-Nucleotide114964590

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Nucleotide114964590
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP-mannose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Nucleotide114964590
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

Dr.    O
Hampikian    O
pioneered    O
the    O
study    O
of    O
DNA    O
and    O
protein    O
sequences    O
absent    O
from    O
nature    O
and    O
coined    O
the    O
term    O
Nullomers    B-Nucleotide114964590
.    O

It    O
is    O
a    O
mixture    O
of    O
disodium    B-Nucleotide114964590
inosinate    I-Nucleotide114964590
(    O
IMP    O
)    O
and    O
disodium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
(    O
GMP    O
)    O
and    O
is    O
often    O
used    O
where    O
a    O
food    O
already    O
contains    O
natural    O
glutamates    O
(    O
as    O
in    O
meat    O
extract    O
)    O
or    O
added    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
.    O

Disodium    B-Nucleotide114964590
inosinate    I-Nucleotide114964590
.    O

Disodium    B-Nucleotide114964590
inosinate    I-Nucleotide114964590
(    O
E631    B-Nucleotide114964590
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

FC    O
(    O
fludarabine    B-Nucleotide114964590
with    O
cyclophosphamide    O
)    O

FR    O
(    O
fludarabine    B-Nucleotide114964590
with    O
rituximab    O
)    O

FCR    O
(    O
fludarabine    B-Nucleotide114964590
,    O
cyclophosphamide    O
,    O
and    O
rituximab    O
)    O

Second    O
line    O
treatment    O
may    O
include    O
fludarabine    B-Nucleotide114964590
,    O
combined    O
with    O
cyclophosphamide    O
and/or    O
mitoxantrone    O
,    O
usually    O
with    O
rituximab    O
.    O

It    O
was    O
approved    O
by    O
the    O
US    O
Food    O
and    O
Drug    O
Administration    O
for    O
CLL    O
patients    O
who    O
have    O
been    O
treated    O
with    O
alkylating    O
agents    O
and    O
who    O
have    O
failed    O
fludarabine    B-Nucleotide114964590
therapy    O
.    O

AICAR    O
+    O
fTHF    O
→    O
FAICAR    B-Nucleotide114964590
+    O
THF    O

SAICAR    O
→    O
AICAR    B-Nucleotide114964590
+    O
Fumarate    O

ASL    O
catalyzes    O
two    O
reactions    O
in    O
the    O
purine    O
biosynthetic    O
pathway    O
that    O
makes    O
AMP    O
;    O
ASL    O
cleaves    O
adenylosuccinate    O
into    O
AMP    O
and    O
fumarate    O
,    O
and    O
cleaves    O
SAICAR    B-Nucleotide114964590
into    O
AICAR    B-Nucleotide114964590
and    O
fumarate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
GDP-mannose    B-Nucleotide114964590
,    O
and    O
one    O
product    O
,    O
GDP    O
-    O
L    O
-    O
galactose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP-mannose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP-mannose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP-mannose    B-Nucleotide114964590
and    O
(    O
phosphomannan)n    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GMP    B-Nucleotide114964590
and    O
(    O
phosphomannan)n+1    O
.    O

bucladesine    B-Nucleotide114964590
(    O
dibutyryl    O
cAMP    O
,    O
db    O
cAMP    O
)    O
-    O
also    O
a    O
phosphodiesterase    O
inhibitor    O

Thymidylate    O
synthetase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
deoxyuridine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
dUMP    O
)    O
to    O
deoxythymidine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
dTMP    O
)    O
.    O

With    O
inhibition    O
of    O
TS    O
,    O
an    O
imbalance    O
of    O
deoxynucleotides    B-Nucleotide114964590
and    O
increased    O
levels    O
of    O
dUMP    B-Nucleotide114964590
arise    O
.    O

By    O
means    O
of    O
reductive    O
methylation    O
,    O
deoxyuridine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
dUMP    O
)    O
and    O
N5,N10-methylene    O
tetrahydrofolate    O
are    O
together    O
used    O
to    O
form    O
dTMP    O
,    O
yielding    O
dihydrofolate    O
as    O
a    O
secondary    O
product    O
.    O

fGAM    O
+    O
ATP    O
→    O
AIR    B-Nucleotide114964590
+    O
ADP    O
+    O
Pi    O
+    O
H2O    O

ASL    O
catalyzes    O
two    O
reactions    O
in    O
the    O
purine    O
biosynthetic    O
pathway    O
that    O
makes    O
AMP    O
;    O
ASL    O
cleaves    O
adenylosuccinate    O
into    O
AMP    O
and    O
fumarate    O
,    O
and    O
cleaves    O
SAICAR    B-Nucleotide114964590
into    O
AICAR    B-Nucleotide114964590
and    O
fumarate    O
.    O

G-quadruplex    B-Nucleotide114964590

In    O
molecular    O
biology    O
,    O
G-quadruplexes    B-Nucleotide114964590
secondary    O
structures    O
formed    O
in    O
nucleic    O
acids    O
by    O
sequences    O
that    O
are    O
rich    O
in    O
guanine    O
.    O

crossing    O
-    O
over    O
(    O
discovered    O
by    O
Thomas    O
Hunt    O
Morgan    O
)    O
mediated    O
by    O
formation    O
and    O
unwinding    O
(    O
by    O
means    O
of    O
peculiar    O
enzymatic    O
complexes    O
such    O
as    O
helicase    O
)    O
of    O
uncommon    O
four    O
-    O
helix    O
DNA    O
structures    O
known    O
as    O
G-quadruplex    B-Nucleotide114964590
(    O
discovered    O
by    O
Martin    O
Gellert    O
,    O
Marie    O
N.    O
Lipsett    O
,    O
and    O
David    O
R.    O
Davies    O
)    O
.    O

Scientists    O
prove    O
that    O
quadruple-helix    B-Nucleotide114964590
DNA    I-Nucleotide114964590
is    O
present    O
in    O
human    O
cells    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    O
and    O
UDP-N-acetyl-D-glucosamine    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
UDP    O
-    O
N    O
-    O
acetyl-3-O-(1-carboxyvinyl)-D    O
-    O
glucosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-N-acetyl-D-glucosamine    B-Nucleotide114964590
and    O
dolichyl    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosaminyl    O
-    O
diphosphodolichol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-N-acetyl-D-glucosamine    B-Nucleotide114964590
and    O
lysosomal    O
-    O
enzyme    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
lysosomal    O
-    O
enzyme    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosaminyl    O
-    O
phospho    O
-    O
D    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-galactose    B-Nucleotide114964590
and    O
UDP-N-acetyl-D-glucosamine    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
UDP    O
-    O
N    O
-    O
acetyl-6-(D    O
-    O
galactose-1-phospho)-D    O
-    O
glucosamine    O
.    O

In    O
eukaryotes    O
,    O
this    O
includes    O
the    O
enzyme    O
GlcNAc    O
phosphotransferase    O
(    O
GPT    O
)    O
,    O
which    O
catalyzes    O
the    O
transfer    O
of    O
N    O
-    O
acetylglucosamine-1-phosphate    O
from    O
UDP-N-acetylglucosamine    B-Nucleotide114964590
to    O
dolichol    O
phosphate    O
in    O
the    O
first    O
step    O
of    O
glycoprotein    O
synthesis    O
.    O

Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
"N"-acetylglucosamine    I-Nucleotide114964590
or    O
UDP-GlcNAc    B-Nucleotide114964590
is    O
a    O
nucleotide    B-Nucleotide114964590
sugar    I-Nucleotide114964590
and    O
a    O
coenzyme    O
in    O
metabolism    O
.    O

Poliovirus    O
has    O
a    O
plus    O
-    O
strand    O
RNA    O
genome    O
,    O
the    O
translation    O
of    O
which    O
depends    O
on    O
a    O
tissue    O
-    O
specific    O
internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590
(    O
IRES    O
)    O
within    O
the    O
5    O
'    O
untranslated    O
region    O
of    O
the    O
viral    O
genome    O
,    O
which    O
is    O
active    O
in    O
cells    O
of    O
neuronal    O
origin    O
and    O
allows    O
translation    O
of    O
the    O
viral    O
genome    O
without    O
a    O
5    O
'    O
cap    O
.    O

Sonenberg    O
also    O
discovered    O
the    O
Internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590
(    O
IRES    O
)    O
mode    O
of    O
translation    O
,    O
the    O
cap    O
-    O
independent    O
initiation    O
of    O
translation    O
,    O
which    O
is    O
critical    O
for    O
some    O
mRNA    O
involved    O
in    O
stress    O
,    O
cell    O
cycling    O
and    O
apoptosis    O
.    O

Picornavirus    O
+    O
ssRNA    O
genome    O
then    O
gets    O
translated    O
via    O
internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590
(    O
IRES    O
)    O
that    O
is    O
recognized    O
by    O
host    O
cell    O
ribosomes    O
for    O
cap    O
independent    O
translation    O
.    O

Several    O
IRESs    B-Nucleotide114964590
also    O
bind    O
eIF4    O
G    O
directly    O
,    O
as    O
do    O
BTE    O
CITEs    O
.    O

Poliovirus    O
utilizes    O
an    O
internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590
(    O
IRES    O
)    O
instead    O
of    O
a    O
cap    O
for    O
translation    O
initiation    O
,    O
abrogating    O
the    O
requirement    O
of    O
VPg    O
in    O
initial    O
infection    O
whereas    O
studies    O
with    O
feline    O
calicivirus    O
confirmed    O
that    O
the    O
VPg    O
protein    O
interacts    O
directly    O
with    O
the    O
cap    O
-    O
binding    O
protein    O
of    O
the    O
ribosome    O
,    O
eIF4E    O
,    O
and    O
that    O
this    O
interaction    O
is    O
essential    O
for    O
viral    O
translation    O
.    O

Internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590
(    O
IRES    O
)    O
are    O
RNA    O
structures    O
that    O
allow    O
for    O
translation    O
initiation    O
in    O
the    O
middle    O
of    O
a    O
mRNA    O
sequence    O
as    O
part    O
of    O
the    O
process    O
of    O
protein    O
synthesis    O
.    O

An    O
internal    O
ribosome    O
entry    O
site    O
,    B-Nucleotide114964590
abbreviated    I-Nucleotide114964590
IRES    I-Nucleotide114964590
,    O
is    O
a    O
RNA    O
element    O
that    O
allows    O
for    O
translation    O
initiation    O
in    O
a    O
cap    O
-    O
independent    O
manner    O
,    O
as    O
part    O
of    O
the    O
greater    O
process    O
of    O
protein    O
synthesis    O
.    O

Internal    B-Nucleotide114964590
ribosome    I-Nucleotide114964590
entry    I-Nucleotide114964590
site    I-Nucleotide114964590

Inosine-5′-monophosphate    B-Nucleotide114964590
dehydrogenase    I-Nucleotide114964590
(    O
IMPDH    O
)    O
is    O
a    O
purine    O
biosynthetic    O
enzyme    O
that    O
catalyzes    O
the    O
nicotinamide    O
adenine    O
dinucleotide    O
(    O
NAD)-dependent    O
oxidation    O
of    O
inosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
IMP    O
)    O
to    O
xanthosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
XMP    O
)    O
,    O
the    O
first    O
committed    O
and    O
rate    O
-    O
limiting    O
step    O
towards    O
the    O
"    O
de    O
novo    O
"    O
biosynthesis    O
of    O
guanine    O
nucleotides    O
from    O
IMP    O
.    O

Thioinosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
(    O
or    O
thioinosine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
,    O
TIMP    B-Nucleotide114964590
)    O
is    O
an    O
intermediate    O
metabolite    O
of    O
azathioprine    O
,    O
an    O
immunosuppressive    O
drug    O
.    O

Pinheiro    O
et    O
al    O
.    O
(    O
2012    O
)    O
demonstrated    O
that    O
the    O
method    O
of    O
polymerase    O
evolution    O
and    O
design    O
successfully    O
led    O
to    O
the    O
storage    O
and    O
recovery    O
of    O
genetic    O
information    O
(    O
of    O
less    O
than    O
100bp    O
length    O
)    O
from    O
six    O
alternative    O
genetic    O
polymers    O
based    O
on    O
simple    O
nucleic    O
acid    O
architectures    O
not    O
found    O
in    O
nature    O
Xeno    B-Nucleotide114964590
nucleic    I-Nucleotide114964590
acid    I-Nucleotide114964590
.    O

Xeno    B-Nucleotide114964590
Nucleic    I-Nucleotide114964590
Acid    I-Nucleotide114964590

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
.    O

They    O
are    O
synthesized    O
by    O
the    O
addition    O
of    O
cytidine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
-    O
ethanolamine    O
to    O
diglycerides    O
,    O
releasing    O
cytidine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP    O
-    O
diacylglycerol    O
and    O
choline    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Nucleotide114964590
and    O
phosphatidylcholine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP    O
-    O
ethanolamine    O
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Nucleotide114964590
and    O
L    O
-    O
serine    O
-    O
phosphoethanolamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP-choline    B-Nucleotide114964590
and    O
sphingosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Nucleotide114964590
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

It    O
is    O
the    O
ribonucleotide    B-Nucleotide114964590
of    O
hypoxanthine    O
and    O
the    O
first    O
nucleotide    O
formed    O
during    O
the    O
synthesis    O
of    O
purine    O
.    O

IMP    O
is    O
an    O
intermediate    O
ribonucleoside    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
in    O
purine    O
metabolism    O
.    O

Ribonucleotide    B-Nucleotide114964590

As    O
RNase    O
A    O
cleaves    O
RNA    O
specifically    O
at    O
cytosine    O
and    O
uracil    O
ribonucleotides    B-Nucleotide114964590
,    O
base    O
-    O
specificity    O
is    O
achieved    O
by    O
adding    O
incorporating    O
cleavage    O
-    O
resistant    O
dTTP    B-Nucleotide114964590
when    O
cytosine    O
-    O
specific    O
(    O
C    O
-    O
specific    O
)    O
cleavage    O
is    O
desired    O
,    O
and    O
incorporating    O
dCTP    O
when    O
uracil    O
-    O
specific    O
(    O
U    O
-    O
specific    O
)    O
cleavage    O
is    O
desired    O
.    O

Its    O
systematic    O
name    O
is    O
YEL021W.    O
URA3    O
is    O
often    O
used    O
in    O
yeast    O
research    O
as    O
a    O
"    O
marker    O
gene    O
"    O
,    O
that    O
is    O
,    O
a    O
gene    O
to    O
label    O
chromosomes    O
or    O
plasmids    O
.    O
URA3    O
encodes    O
Orotidine    O
5'-phosphate    O
decarboxylase    O
(    O
ODCase    O
)    O
,    O
which    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
one    O
reaction    O
in    O
the    O
synthesis    O
of    O
pyrimidine    O
ribonucleotides    B-Nucleotide114964590
(    O
a    O
component    O
of    O
RNA    O
)    O
.    O

In    O
molecular    O
biology    O
,    O
the    O
ATP    O
-    O
cone    O
is    O
an    O
evolutionarily    O
mobile    O
,    O
ATP    O
-    O
binding    O
regulatory    O
domain    O
which    O
is    O
found    O
in    O
a    O
variety    O
of    O
proteins    O
including    O
ribonucleotide    B-Nucleotide114964590
reductases    O
,    O
phosphoglycerate    O
kinases    O
and    O
transcriptional    O
regulators    O
.    O

The    O
galactose    O
component    O
originates    O
from    O
UDP-galactose    B-Nucleotide114964590
and    O
the    O
GalNAc    O
component    O
originates    O
from    O
UDP    O
-    O
N    O
-    O
acetylgalactosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-galactose    B-Nucleotide114964590
and    O
UDP-N-acetyl-D-glucosamine    B-Nucleotide114964590
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
UDP    O
-    O
N    O
-    O
acetyl-6-(D    O
-    O
galactose-1-phospho)-D    O
-    O
glucosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-glucose    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
and    O
UDP-galactose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP-galactose    B-Nucleotide114964590
and    O
undecaprenyl    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactosyl    O
-    O
diphosphoundecaprenol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP-galactose    B-Nucleotide114964590
.    O

With    O
inhibition    O
of    O
TS    O
,    O
an    O
imbalance    O
of    O
deoxynucleotides    B-Nucleotide114964590
and    O
increased    O
levels    O
of    O
dUMP    B-Nucleotide114964590
arise    O
.    O

Deoxynucleotides    B-Nucleotide114964590
are    O
then    O
added    O
to    O
this    O
primer    O
by    O
a    O
single    O
DNA    O
polymerase    O
III    O
dimer    O
,    O
in    O
an    O
integrated    O
complex    O
with    O
DnaB    O
helicase    O
.    O

First    O
,    O
an    O
RNA    O
primer    O
is    O
synthesized    O
by    O
primase    O
,    O
and    O
,    O
like    O
that    O
in    O
leading    O
strand    O
synthesis    O
,    O
DNA    O
Pol    O
III    O
binds    O
to    O
the    O
RNA    O
primer    O
and    O
adds    O
deoxyribonucleotide    B-Nucleotide114964590
.    O

A    O
similar    O
process    O
occurs    O
in    O
the    O
formation    O
of    O
DNA    O
,    O
except    O
that    O
ATP    O
is    O
first    O
converted    O
to    O
the    O
deoxyribonucleotide    B-Nucleotide114964590
dATP    O
.    O

database    O
search    O
-    O
degeneracy    O
(    O
biology    O
)    O
-    O
deletion    O
-    O
denaturation    O
-    O
denaturing    O
gel    O
-    O
deoxyribonuclease    O
(    O
DNase    O
)    O
-    O
deoxyribonucleic    O
acid    O
-    O
deoxyribonucleotide    B-Nucleotide114964590
-    O
diabetes    O
mellitus    O
-    O
dideoxy    O
sequencing    O
-    O
dideoxyribonucleotide    B-Nucleotide114964590
-    O
diploid    O
-    O
direct    O
repeat    O
-    O
DNA    O
ligase    O
-DNA    O
Bank    O
-    O
DNA    O
polymerase    O
-    O
DNA    O
replication    O
-    O
DNA    O
sequencing    O
-    O
DNase    O
-    O
dominant    O
-    O
dot    O
blot    O
-    O
double    O
helix    O
-    O
downstream    O
(    O
DNA    O
)    O
-    O
downstream    O
(    O
transduction    O
)    O
-    O
ds    O
-    O
duplex    O
-    O

These    O
activated    O
biochemical    O
intermediates    O
are    O
known    O
as    O
sugar    B-Nucleotide114964590
nucleotide    I-Nucleotide114964590
or    O
sugar    O
donors    O
.    O

Uridine    B-Nucleotide114964590
diphosphate    I-Nucleotide114964590
"N"-acetylglucosamine    I-Nucleotide114964590
or    O
UDP-GlcNAc    B-Nucleotide114964590
is    O
a    O
nucleotide    B-Nucleotide114964590
sugar    I-Nucleotide114964590
and    O
a    O
coenzyme    O
in    O
metabolism    O
.    O

It    O
is    O
often    O
added    O
to    O
foods    O
in    O
conjunction    O
with    O
disodium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
;    O
the    O
combination    O
is    O
known    O
as    O
disodium    B-Nucleotide114964590
5'-ribonucleotides    I-Nucleotide114964590
.    O

In    O
contrast    O
,    O
8-bromoadenosine    B-Nucleotide114964590
3',5'-cyclic    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
8-bromo    O
-    O
cAMP    O
)    O
down    O
-    O
regulates    O
VLDLR    O
expression    O
.    O

Adenosine    B-Nucleotide114964590
thiamine    I-Nucleotide114964590
triphosphate    I-Nucleotide114964590
(    O
AThTP    O
)    O
or    O
thiaminylated    O
adenosine    O
triphosphate    O
has    O
recently    O
been    O
discovered    O
in    O
"    O
Escherichia    O
coli    O
"    O
,    O
where    O
it    O
accumulates    O
as    O
a    O
result    O
of    O
carbon    O
starvation    O
.    O

Thymidylate    O
synthetase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
deoxyuridine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
dUMP    O
)    O
to    O
deoxythymidine    B-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
dTMP    O
)    O
.    O

Dihydrofolate    O
reductase    O
converts    O
dihydrofolate    O
into    O
tetrahydrofolate    O
,    O
a    O
methyl    O
group    O
shuttle    O
required    O
for    O
the    O
de    O
novo    O
synthesis    O
of    O
purines    O
,    O
thymidylic    B-Nucleotide114964590
acid    I-Nucleotide114964590
,    O
and    O
certain    O
amino    O
acids    O
.    O

Tetrahydrofolate    O
and    O
its    O
derivatives    O
are    O
essential    O
for    O
purine    O
and    O
thymidylate    B-Nucleotide114964590
synthesis    O
,    O
which    O
are    O
important    O
for    O
cell    O
proliferation    O
and    O
cell    O
growth    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
,    O
dGMP    O
,    O
and    O
dTMP    B-Nucleotide114964590
,    O
whereas    O
its    O
3    O
products    O
are    O
ADP    O
,    O
dGDP    O
,    O
and    O
dTDP    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
thymidylate    B-Nucleotide114964590
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
thymidine    O
and    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Nucleotide114964590
and    O
sn    O
-    O
glycerol    O
3-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
glycerol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Nucleotide114964590
and    O
N    O
-    O
acylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CMP    O
-    O
N    O
-    O
acylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Nucleotide114964590
and    O
N    O
-    O
methylethanolamine    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
N    O
-    O
methylethanolamine    O
.    O

Phosphatidate    O
cytidylyltransferase    O
(    O
also    O
known    O
as    O
CDP-    O
diacylglycerol    O
synthase    O
)    O
(    O
CDS    O
)    O
is    O
the    O
enzyme    O
that    O
catalyzes    O
the    O
synthesis    O
of    O
CDP    O
-    O
diacylglycerol    O
from    O
cytidine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
and    O
phosphatidate    O
.    O

However    O
,    O
archaeal    O
riboflavin    O
kinases    O
in    O
general    O
utilize    O
CTP    B-Nucleotide114964590
rather    O
than    O
ATP    O
as    O
the    O
donor    O
nucleotide    O
,    O
catalyzing    O
the    O
reaction    O

While    O
trying    O
to    O
isolate    O
the    O
bacterial    O
toxin    O
responsible    O
for    O
tuberculosis    O
,    O
W.G.    O
Ruppel    O
isolated    O
a    O
novel    O
nucleic    O
acid    O
named    O
tuberculinic    B-Nucleotide114964590
acid    I-Nucleotide114964590
in    O
1898    O
from    O
"    O
Tubercle    O
bacillus    O
"    O
.    O

Dipotassium    B-Nucleotide114964590
guanylate    I-Nucleotide114964590
is    O
a    O
compound    O
with    O
formula    O
K2(C10H12O4N5PO4    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
dCMP    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
dCDP    B-Nucleotide114964590
.    O

Arabinofuranosylcytosine    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590

If    O
there    O
is    O
sufficient    O
DNA    O
to    O
measure    O
both    O
mass    O
and    O
average    O
length    O
,    O
it    O
is    O
possible    O
to    O
determine    O
the    O
proper    O
amount    O
of    O
dATP    B-Nucleotide114964590
to    O
be    O
added    O
to    O
generate    O
poly(dA    O
)    O
tails    O
90    O
to    O
200    O
nucleotides    O
long    O
.    O

Nucleic    O
acids    O
can    O
only    O
be    O
synthesized    O
in    O
vivo    O
in    O
the    O
5′-to-3′    O
direction    O
,    O
as    O
the    O
polymerases    O
that    O
assemble    O
various    O
types    O
of    O
new    O
strands    O
generally    O
rely    O
on    O
the    O
energy    O
produced    O
by    O
breaking    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
bonds    O
to    O
attach    O
new    O
nucleoside    O
monophosphates    O
to    O
the    O
3′-hydroxyl    O
(    O
-OH    O
)    O
group    O
,    O
via    O
a    O
phosphodiester    O
bond    O
.    O

The    O
enzyme    O
hydrolyses    O
oxidizes    O
purine    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
and    O
gentamicin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
2"-nucleotidylgentamicin    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
and    O
AMP    O
,    O
whereas    O
its    O
two    O
products    O
are    O
nucleoside    O
diphosphate    O
and    O
ADP    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
aldose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
NDP    O
-    O
hexose    O
.    O

From    O
the    O
perspective    O
of    O
biochemistry    O
,    O
ATP    O
is    O
classified    O
as    O
a    O
nucleoside    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
,    O
which    O
indicates    O
that    O
it    O
consists    O
of    O
three    O
components    O
,    O
a    O
nitrogenous    O
base    O
(    O
adenine    O
)    O
,    O
the    O
sugar    O
ribose    O
,    O
and    O
the    O
triphosphate    O
.    O

From    O
the    O
circular    O
DNA    O
template    O
,    O
single    O
-    O
stranded    O
RNA    O
varying    O
in    O
length    O
from    O
4    O
-    O
1500    O
bp    O
can    O
be    O
produced    O
without    O
the    O
need    O
for    O
primers    O
and    O
by    O
recycling    O
nucleotide    B-Nucleotide114964590
triphosphate    I-Nucleotide114964590
.    O

While    O
ATP    O
is    O
used    O
by    O
DGK    O
in    O
mammalian    O
cells    O
,    O
yeast    O
cells    O
tend    O
to    O
use    O
CTP    B-Nucleotide114964590
as    O
the    O
high    O
-    O
energy    O
phosphate    O
donor    O
instead    O
.    O

Protein    O
recognition    O
at    O
the    O
receptor    O
uses    O
cAMP    B-Nucleotide114964590
as    O
a    O
secondary    O
messenger    O
.    O

When    O
bound    O
,    O
the    O
receptor    O
couples    O
to    O
G    O
-    O
protein    O
alpha    O
subunit    O
,    O
activates    O
adenylyl    O
cyclase    O
,    O
and    O
increases    O
cAMP    B-Nucleotide114964590
production    O
.    O

During    O
ovulation    O
,    O
the    O
surge    O
in    O
luteinizing    O
hormone    O
increases    O
cAMP    B-Nucleotide114964590
which    O
increases    O
progesterone    O
and    O
PGF2α    O
production    O
.    O

Some    O
of    O
these    O
pathways    O
include    O
Rap    O
,    O
Erk1/2    O
,    O
MAPK    O
,    O
B    O
-    O
RAF    O
,    O
PI3-K    O
,    O
cAMP    B-Nucleotide114964590
,    O
PKA    O
,    O
and    O
TORC2    O
that    O
are    O
activated    O
to    O
initiate    O
exocytosis    O
,    O
proinsulin    O
gene    O
expression    O
and    O
translation    O
,    O
increase    O
insulin    O
biosynthesis    O
,    O
and    O
genetically    O
increase    O
beta    O
cell    O
proliferation    O
and    O
neogenesis    O
.    O

Prostaglandin    O
E1    O
(    O
PGE1    O
)    O
is    O
a    O
platelet    O
inhibitor    O
that    O
causes    O
an    O
increase    O
in    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
in    O
platelets    O
by    O
stimulating    O
adenylyl    O
cyclase    O
activity    O
.    O

In    O
"    O
Dictyostelium    O
"    O
,    O
aggregation    O
is    O
signalled    O
by    O
cAMP    B-Nucleotide114964590
,    O
but    O
others    O
use    O
different    O
chemicals    O
.    O

The    O
mechanism    O
behind    O
the    O
aggregation    O
of    O
the    O
amoebae    O
relies    O
on    O
Cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
as    O
a    O
signal    O
molecule    O
.    O

By    O
comparison    O
,    O
"    O
N    O
"-    O
methyldopamine    O
also    O
had    O
no    O
effect    O
in    O
caudectomized    O
mice    O
at    O
≤    O
150    O
mg    O
/    O
kg    O
,    O
and    O
only    O
a    O
weak    O
effect    O
in    O
nigral    O
-    O
lesioned    O
rats    O
at    O
25    O
mg    O
/    O
kg    O
,    O
although    O
it    O
was    O
as    O
effective    O
as    O
dopamine    O
in    O
stimulating    O
cAMP    B-Nucleotide114964590
in    O
the    O
adenylate    O
cyclase    O
assay    O
.    O

Upregulation    O
of    O
the    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
signal    O
transduction    O
pathway    O
by    O
cAMP    O
response    O
element    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
a    O
gene    O
transcription    O
factor    O
,    O
in    O
the    O
nucleus    O
accumbens    O
is    O
a    O
common    O
mechanism    O
of    O
psychological    O
dependence    O
among    O
several    O
classes    O
of    O
drugs    O
of    O
abuse    O
.    O

When    O
stimulated    O
,    O
it    O
increases    O
cAMP    B-Nucleotide114964590
levels    O
,    O
in    O
turn    O
leading    O
to    O
CREB    O
activation    O
.    O

The    O
α    O
subunit    O
is    O
thought    O
to    O
be    O
the    O
effector    O
region    O
responsible    O
for    O
stimulation    O
of    O
adenylate    O
cyclase    O
(    O
involved    O
the    O
generation    O
of    O
cAMP    B-Nucleotide114964590
)    O
.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
and    O
cyclic    B-Nucleotide114964590
guanosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Nucleotide114964590
and    O
cGMP    B-Nucleotide114964590
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
’s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Nucleotide114964590
or    O
cGMP    B-Nucleotide114964590
.    O

Transcription    O
of    O
the    O
"    O
lsr    O
"    O
operon    O
is    O
also    O
thought    O
to    O
be    O
inhibited    O
by    O
dihydroxyacetone    O
phosphate    O
(    O
DHAP    O
)    O
through    O
its    O
competitive    O
binding    O
to    O
LsrR.    O
Glyceraldehyde    O
3-phosphate    O
has    O
also    O
been    O
shown    O
to    O
inhibit    O
the    O
"    O
lsr    O
"    O
operon    O
through    O
cAMP    B-Nucleotide114964590
-    O
CAPK    O
-    O
mediated    O
inhibition    O
.    O

The    O
following    O
table    O
gives    O
these    O
receptors    O
:    O
a    O
)    O
full    O
name    O
;    O
b    O
)    O
shortened    O
names    O
;    O
c    O
)    O
activating    O
prostanoids    O
(    O
presented    O
in    O
order    O
of    O
decreasing    O
potencies    O
)    O
;    O
d    O
)    O
time    O
-    O
honored    O
classification    O
as    O
contractile    O
(    O
i.e.    O
conracting    O
smooth    O
muscle    O
)    O
,    O
relaxant    O
(    O
i.e.    O
relaxing    O
smooth    O
muscle    O
)    O
,    O
or    O
inhibitory    O
(    O
i.e.    O
inhibiting    O
adenyl    O
cyclase    O
(    O
AC    O
)    O
production    O
of    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
[    O
cAMP    O
]    O
)    O
;    O
e    O
)    O
G    O
proteins    O
types    O
to    O
which    O
they    O
link    O
and    O
activate    O
,    O
i.e.    O
those    O
containing    O
the    O
Gs    O
alpha    O
subunit    O
,    O
Gi    O
alpha    O
subunit    O
,    O
Gq    O
alpha    O
subunit    O
and/or    O
G12    O
subunit    O
;    O
and    O
f    O
)    O
signaling    O
pathways    O
which    O
they    O
regulate    O
including    O
Adenyl    O
cyclase    O
which    O
when    O
activated    O
increases    O
cellular    O
cAMP    B-Nucleotide114964590
and    O
when    O
inhibited    O
reduces    O
the    O
cellular    O
levels    O
of    O
this    O
secondary    O
messenger    O
;    O
Phosphoinositide    O
3-kinase    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
phosphatidylinositol    O
3-phosphate    O
,    O
phosphatidylinositol    O
(    O
3,4)-bisphosphate    O
,    O
and    O
phosphatidylinositol    O
(    O
3,4,5)-trisphosphate    O
secondary    O
messengers    O
;    O
Phospholipase    O
C    O
(    O
PLC    O
)    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
Inositol    O
trisphosphate    O
(    O
IP3    O
)    O
and    O
diacylglycerol    O
secondary    O
messengers    O
that    O
are    O
,    O
respectively    O
,    O
responsible    O
for    O
raising    O
the    O
levels    O
of    O
Ca2    O
+    O
in    O
the    O
cellular    O
cytosol    O
to    O
control    O
the    O
activity    O
of    O
Ca2    O
+    O
-cell    O
signaling    O
agents    O
and    O
for    O
activating    O
protein    O
kinase    O
C    O
(    O
PKC    O
)    O
secondary    O
messengers    O
;    O
and    O
Extracellular    O
signal    O
–    O
regulated    O
kinases    O
(    O
ERK    O
)    O
,    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinases    O
(    O
p38    O
Mpk    O
)    O
,    O
and    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
which    O
when    O
activated    O
phosphorylate    O
and    O
thereby    O
influence    O
the    O
activity    O
of    O
key    O
proteins    O
that    O
govern    O
cell    O
function    O
.    O

First    O
isolated    O
as    O
a    O
nuclear    O
protein    O
that    O
binds    O
to    O
cAMP    B-Nucleotide114964590
-    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
this    O
gene    O
is    O
now    O
known    O
to    O
play    O
critical    O
roles    O
in    O
embryonic    O
development    O
,    O
growth    O
control    O
,    O
and    O
homeostasis    O
by    O
coupling    O
chromatin    O
remodeling    O
to    O
transcription    O
factor    O
recognition    O
.    O

This    O
leads    O
to    O
inhibition    O
of    O
adenylyl    O
cyclase    O
and    O
lactose    O
permease    O
,    O
therefore    O
cAMP    B-Nucleotide114964590
levels    O
are    O
low    O
and    O
lactose    O
can    O
not    O
be    O
transported    O
inside    O
the    O
bacteria    O
.    O

When    O
glucose    O
levels    O
are    O
low    O
the    O
phosphorylated    O
form    O
of    O
EIIA    O
accumulates    O
and    O
consequently    O
activates    O
the    O
enzyme    O
adenylyl    O
cyclase    O
,    O
which    O
will    O
produce    O
high    O
levels    O
of    O
cAMP    B-Nucleotide114964590
.    O

Gram    O
positive    O
bacteria    O
such    O
as    O
"    O
Bacillus    O
subtilis    O
"    O
have    O
a    O
cAMP    B-Nucleotide114964590
-    O
independent    O
catabolite    O
repression    O
mechanism    O
controlled    O
by    O
catabolite    O
control    O
protein    O
A    O
(    O
CcpA    O
)    O
.    O

In    O
particular    O
,    O
Gαs    O
stimulates    O
adenyl    O
cyclase    O
to    O
raise    O
cellular    O
levels    O
of    O
cAMP    B-Nucleotide114964590
thereby    O
activating    O
PKA    O
;    O
PKA    O
activates    O
various    O
types    O
of    O
signaling    O
molecules    O
such    O
as    O
the    O
transcription    O
factor    O
CREB    O
which    O
lead    O
to    O
different    O
types    O
of    O
functional    O
responses    O
depending    O
on    O
cell    O
type    O
.    O

,    O
pathways    O
that    O
activate    O
phospholipase    O
C    O
to    O
convert    O
cellular    O
phospholipids    O
to    O
diacylglycerol    O
which    O
promotes    O
the    O
activation    O
of    O
certain    O
isoforms    O
of    O
protein    O
kinase    O
C    O
,    O
pathways    O
that    O
elevated    O
cellular    O
cytosolic    O
Ca2    O
+    O
which    O
thereby    O
regulate    O
Ca2    O
+    O
-sensitive    O
cell    O
signaling    O
molecules    O
,    O
and    O
pathways    O
that    O
inhibit    O
adenyl    O
cyclase    O
which    O
thereby    O
lowers    O
cellular    O
levels    O
of    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
to    O
reduce    O
the    O
activity    O
of    O
cAMP    O
-    O
dependent    O
signaling    O
molecules    O
.    O

After    O
binding    O
to    O
calmodulin    O
,    O
cyaA    O
–    O
ACD    O
catalyzes    O
the    O
cyclization    O
of    O
AMP    O
into    O
cAMP    B-Nucleotide114964590
.    O

"    O
Genetically    O
engineered    O
mice    O
"    O
:    O
Only    O
few    O
generated    O
mutant    O
lines    O
can    O
be    O
regarded    O
as    O
depression    O
models    O
,    O
for    O
example    O
,    O
α2A    O
adrenergic    O
receptor    O
knockout    O
mice    O
,    O
glucocorticoid    O
receptor    O
heterozygous    O
mice    O
,    O
and    O
cAMP    B-Nucleotide114964590
response    O
element    O
-    O
binding    O
protein    O
overexpressing    O
mice    O
.    O

When    O
the    O
β2-agonist    O
binds    O
and    O
activates    O
the    O
β2-adrenoreceptor    O
intracellular    O
signaling    O
becomes    O
largely    O
affected    O
through    O
cyclic    O
adenosine    O
monophosphate    O
(    O
cAMP    B-Nucleotide114964590
)    O
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
.    O

1971    O
-    O
Earl    O
W.    O
Sutherland    O
(    O
Chair    O
of    O
Pharmacology    O
)    O
,    O
Nobel    O
Prize    O
in    O
Physiology    O
or    O
Medicine    O
,    O
for    O
establishing    O
identity    O
and    O
importance    O
of    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
or    O
cyclic    O
AMP    O
in    O
regulation    O
of    O
cell    O
metabolism    O
.    O

Rodent    O
studies    O
have    O
consistently    O
shown    O
upregulation    O
of    O
the    O
3,    B-Nucleotide114964590
5-cyclic    I-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O
system    O
induced    O
by    O
different    O
types    O
of    O
chronic    O
but    O
not    O
acute    O
antidepressant    O
treatment    O
,    O
including    O
serotonin    O
and    O
norepinephrine    O
uptake    O
inhibitors    O
,    O
monoamine    O
oxidase    O
inhibitors    O
,    O
tricyclic    O
antidepressants    O
,    O
lithium    O
and    O
electroconvulsions    O
.    O

Cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
or    O
cyclic    O
AMP    O
)    O
is    O
a    O
second    O
messenger    O
that    O
has    O
been    O
implicated    O
in    O
facilitating    O
mushroom    O
body    O
calcium    O
influx    O
in    O
Drosophila    O
melanogaster    O
MBNs    O
.    O

In    O
a    O
classical    O
conditioning    O
paradigm    O
,    O
pairing    O
neuronal    O
depolarization    O
(    O
via    O
acetylcholine    O
application    O
to    O
represent    O
the    O
odor    O
or    O
CS    O
)    O
with    O
subsequent    O
dopamine    O
application    O
(    O
to    O
represent    O
the    O
shock    O
or    O
US    O
)    O
,    O
results    O
in    O
a    O
synergistic    O
increase    O
in    O
cAMP    B-Nucleotide114964590
in    O
the    O
mushroom    O
body    O
lobes    O
.    O

This    O
AC    O
activation    O
increases    O
the    O
concentration    O
of    O
cAMP    B-Nucleotide114964590
,    O
which    O
activates    O
PKA    O
.    O

For    O
example    O
,    O
the    O
cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(cAMP)    I-Nucleotide114964590
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
pathways    O
appear    O
to    O
participate    O
in    O
neuronal    O
allocation    O
.    O

When    O
activated    O
by    O
the    O
second    O
messengers    O
such    O
as    O
cAMP    B-Nucleotide114964590
and    O
calcium    O
ions    O
,    O
enzymes    O
such    O
as    O
PKA    O
and    O
MAP    O
kinase    O
can    O
translocate    O
to    O
the    O
nucleus    O
and    O
phosphorylate    O
CREB    O
to    O
initiate    O
transcription    O
of    O
target    O
genes    O
.    O

In    O
decidual    O
cells    O
and    O
in    O
lymphocytes    O
the    O
distal    O
promoter    O
and    O
thus    O
prolactin    O
expression    O
is    O
stimulated    O
by    O
cAMP    B-Nucleotide114964590
.    O

Resting    O
platelets    O
maintain    O
active    O
calcium    O
efflux    O
via    O
a    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
activated    O
calcium    O
pump    O
.    O

It    O
is    O
thought    O
that    O
regulation    O
of    O
argininosuccinate    O
synthetase    O
activity    O
in    O
arginine    O
synthesis    O
occurs    O
primarily    O
at    O
the    O
transcriptional    O
level    O
in    O
response    O
to    O
glucocorticoids    O
,    O
cAMP    B-Nucleotide114964590
,    O
glucagon    O
,    O
and    O
insulin    O
.    O

Recently    O
,    O
it    O
has    O
been    O
noted    O
that    O
extrasynaptic    O
NMDA    O
receptor    O
activation    O
,    O
triggered    O
by    O
both    O
glutamate    O
exposure    O
or    O
hypoxic    O
/    O
ischemic    O
conditions    O
,    O
activate    O
a    O
CREB    O
(    O
cAMP    B-Nucleotide114964590
response    O
element    O
binding    O
)    O
protein    O
shut    O
-    O
off    O
,    O
which    O
in    O
turn    O
caused    O
loss    O
of    O
mitochondrial    O
membrane    O
potential    O
and    O
apoptosis    O
.    O

He    O
elucidated    O
the    O
pleiotropic    O
functions    O
of    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
in    O
Escherichia    O
coli    O
and    O
elaborated    O
on    O
the    O
antitermination    O
and    O
antiparallel    O
transcription    O
and    O
transcription    O
termination    O
sites    O
of    O
Lambda    O
phage    O
.    O

A    O
number    O
of    O
other    O
small    O
molecules    O
can    O
compensate    O
for    O
the    O
ATP    O
-    O
induced    O
shift    O
in    O
equilibrium    O
conformation    O
and    O
reactivate    O
PFK    O
,    O
including    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
,    O
ammonium    O
ions    O
,    O
inorganic    O
phosphate    O
,    O
and    O
fructose-1,6-    O
and    O
-2,6-biphosphate    O
.    O

Cyclic    B-Nucleotide114964590
adenosine    I-Nucleotide114964590
monophosphate    I-Nucleotide114964590
(    O
cAMP    O
)    O

While    O
it    O
is    O
known    O
that    O
myosin    O
phosphatase    O
is    O
regulated    O
by    O
rho    O
-    O
associated    O
protein    O
kinases    O
,    O
there    O
is    O
current    O
debate    O
about    O
whether    O
other    O
molecules    O
,    O
such    O
as    O
arachidonic    O
acid    O
and    O
cAMP    B-Nucleotide114964590
,    O
also    O
regulate    O
the    O
enzyme    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
(    O
this    O
receptor    O
)    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

cAMP    B-Nucleotide114964590

The    O
5-HT7    O
receptor    O
is    O
a    O
member    O
of    O
the    O
GPCR    O
superfamily    O
of    O
cell    O
surface    O
receptors    O
and    O
is    O
activated    O
by    O
the    O
neurotransmitter    O
serotonin    O
(    O
5-hydroxytryptamine    O
,    O
5-HT    O
)    O
The    O
5-HT7    O
receptor    O
is    O
coupled    O
to    O
Gs    O
(    O
stimulates    O
the    O
production    O
of    O
the    O
intracellular    O
signaling    O
molecule    O
cAMP    B-Nucleotide114964590
)    O
and    O
is    O
expressed    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
,    O
particularly    O
in    O
the    O
brain    O
,    O
the    O
gastrointestinal    O
tract    O
,    O
and    O
in    O
various    O
blood    O
vessels    O
.    O

Gs    O
in    O
turn    O
activates    O
adenylate    O
cyclase    O
which    O
increases    O
intracellular    O
levels    O
of    O
the    O
second    O
messenger    O
cAMP    B-Nucleotide114964590
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Nucleotide114964590
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Nucleotide114964590
.    O

cAMP    B-Nucleotide114964590
impairs    O
platelet    O
aggregation    O
and    O
also    O
causes    O
arteriolar    O
smooth    O
muscle    O
relaxation    O
.    O

Transcription    O
activation    O
requires    O
the    O
binding    O
of    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
and    O
maltotriose    O
to    O
MalT    O
and    O
the    O
binding    O
of    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
to    O
the    O
dimer    O
of    O
CRP    O
.    O

JDP2    O
regulates    O
12-O    O
-    O
tetradecanoylphorbol-13-acetate    O
(    O
TPA    O
)    O
response    O
element    O
(    O
TRE)-    O
and    O
cAMP    B-Nucleotide114964590
-    O
responsive    O
element    O
(    O
CRE)-dependent    O
transcription    O
.    O

The    O
rationale    O
for    O
use    O
of    O
these    O
drugs    O
was    O
their    O
ability    O
to    O
increase    O
intracellular    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
(    O
adenosine    O
monophosphate    O
)    O
levels    O
,    O
which    O
might    O
counteract    O
inflammatory    O
signaling    O
pathways    O
that    O
induce    O
endothelial    O
permeability    O
.    O

With    O
Robert    O
L.    O
Perlman    O
he    O
established    O
the    O
first    O
general    O
mechanism    O
of    O
positive    O
gene    O
regulation    O
in    O
bacteria    O
,    O
showing    O
that    O
cyclic    B-Nucleotide114964590
AMP    I-Nucleotide114964590
and    O
its    O
receptor    O
protein    O
CRP    O
(    O
cyclic    O
AMP    O
receptor    O
protein    O
)    O
positively    O
regulated    O
the    O
activity    O
of    O
many    O
genes    O
.    O

MT1302    O
encodes    O
an    O
adenylyl    O
cyclase    O
that    O
converts    O
ATP    O
to    O
cAMP    B-Nucleotide114964590
,    O
the    O
expression    O
of    O
ncrMT1302    O
is    O
regulated    O
by    O
cAMP    O
and    O
pH.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
RNAn    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
RNAn+1    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and[N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
glucosamine    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP-galactose    B-Nucleotide114964590
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
monosaccharide    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
monosaccharide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Nucleotide114964590
and    O
alpha    O
-    O
D    O
-    O
xylose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
xylose    O
.    O


